<html lang="en" class="pb-page js" data-request-id="94d676f5c713f24b-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d676f5c713f24b-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/JbtvNw4AKfcGCVmShxLbedye7pWUBrXrpAIftRCc-jZ7lqYvp9m7Oy9xPolZ4k5z2KMoR4epTj87fMhP769mVg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d676f5c713f24b-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.8722570895822348"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Hematology/Oncology General|Treatments in Oncology|Nephrology General">
<meta name="Specialties" content="Nephrology|Hematology/Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2035716","title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","category":"Research","type":"Original Article","topics":"Hematology/Oncology General|Treatments in Oncology|Nephrology General","specialties":"Nephrology|Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-04-08T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Hematology/Oncology General|Treatments in Oncology|Nephrology General\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Nephrology|Hematology/Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2035716","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","doi":"10.1056/NEJMdo006000","issueDate":"2021-04-08T00:00Z","age":"6Months-1990","isFree":"y","topics":"Hematology/Oncology General|Treatments in Oncology|Nephrology General","viewType":"Full","specialties":"Nephrology|Hematology/Oncology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d676f5c713f24b-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma"><meta name="dc.Creator" content="Robert Motzer"><meta name="dc.Creator" content="Boris Alekseev"><meta name="dc.Creator" content="Sun-Young Rha"><meta name="dc.Creator" content="Camillo Porta"><meta name="dc.Creator" content="Masatoshi Eto"><meta name="dc.Creator" content="Thomas Powles"><meta name="dc.Creator" content="Viktor Grünwald"><meta name="dc.Creator" content="Thomas E. Hutson"><meta name="dc.Creator" content="Evgeny Kopyltsov"><meta name="dc.Creator" content="María J. Méndez-Vidal"><meta name="dc.Creator" content="Vadim Kozlov"><meta name="dc.Creator" content="Anna Alyasova"><meta name="dc.Creator" content="Sung-Hoo Hong"><meta name="dc.Creator" content="Anil Kapoor"><meta name="dc.Creator" content="Teresa Alonso Gordoa"><meta name="dc.Creator" content="Jaime R. Merchan"><meta name="dc.Creator" content="Eric Winquist"><meta name="dc.Creator" content="Pablo Maroto"><meta name="dc.Creator" content="Jeffrey C. Goh"><meta name="dc.Creator" content="Miso Kim"><meta name="dc.Creator" content="Howard Gurney"><meta name="dc.Creator" content="Vijay Patel"><meta name="dc.Creator" content="Avivit Peer"><meta name="dc.Creator" content="Giuseppe Procopio"><meta name="dc.Creator" content="Toshio Takagi"><meta name="dc.Creator" content="Bohuslav Melichar"><meta name="dc.Creator" content="Frederic Rolland"><meta name="dc.Creator" content="Ugo De Giorgi"><meta name="dc.Creator" content="Shirley Wong"><meta name="dc.Creator" content="Jens Bedke"><meta name="dc.Creator" content="Manuela Schmidinger"><meta name="dc.Creator" content="Corina E. Dutcus"><meta name="dc.Creator" content="Alan D. Smith"><meta name="dc.Creator" content="Lea Dutta"><meta name="dc.Creator" content="Kalgi Mody"><meta name="dc.Creator" content="Rodolfo F. Perini"><meta name="dc.Creator" content="Dongyuan Xing"><meta name="dc.Creator" content="Toni K. Choueiri"><meta name="dc.Description" content="Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.In this p..."><meta name="Description" content="Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.In this p..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-04-08"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2035716"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202104083841405"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2101777"><meta name="dc.Relation" content="YXQYoa2035716"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2035716">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2035716">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2035716">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | NEJM">
        <meta property="og:title" content="Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2035716">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/67b0cb54-4861-4465-8bb4-e241e025fc50/nejmoa2035716_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/67b0cb54-4861-4465-8bb4-e241e025fc50/nejmoa2035716_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced
renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib
is unclear. In this ...">
        <meta name="twitter:description" content="Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced
renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib
is unclear. In this ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3065">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2035716">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2035716">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2035716;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;issue:issue:doi\:10.1056/nejm_2021.384.issue-14;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035716" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035716" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035716" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2035716" class="inputDoi"><input type="hidden" value="R. Motzer and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:1289-1300" class="inputCitation"><input type="hidden" value="02-13-2021" class="inputEPubDate"><input type="hidden" value="April 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d676f5c713f24b-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Motzer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Boris</span> <span property="familyName">Alekseev</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sun-Young</span> <span property="familyName">Rha</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Camillo</span> <span property="familyName">Porta</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Masatoshi</span> <span property="familyName">Eto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas</span> <span property="familyName">Powles</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Viktor</span> <span property="familyName">Grünwald</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+31</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas E.</span> <span property="familyName">Hutson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Evgeny</span> <span property="familyName">Kopyltsov</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">María J.</span> <span property="familyName">Méndez-Vidal</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vadim</span> <span property="familyName">Kozlov</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anna</span> <span property="familyName">Alyasova</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sung-Hoo</span> <span property="familyName">Hong</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anil</span> <span property="familyName">Kapoor</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Teresa</span> <span property="familyName">Alonso Gordoa</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jaime R.</span> <span property="familyName">Merchan</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eric</span> <span property="familyName">Winquist</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pablo</span> <span property="familyName">Maroto</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jeffrey C.</span> <span property="familyName">Goh</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Miso</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Howard</span> <span property="familyName">Gurney</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vijay</span> <span property="familyName">Patel</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Avivit</span> <span property="familyName">Peer</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Giuseppe</span> <span property="familyName">Procopio</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Toshio</span> <span property="familyName">Takagi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bohuslav</span> <span property="familyName">Melichar</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Frederic</span> <span property="familyName">Rolland</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ugo</span> <span property="familyName">De Giorgi</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7520-2908" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7520-2908</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shirley</span> <span property="familyName">Wong</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jens</span> <span property="familyName">Bedke</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Manuela</span> <span property="familyName">Schmidinger</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Corina E.</span> <span property="familyName">Dutcus</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alan D.</span> <span property="familyName">Smith</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lea</span> <span property="familyName">Dutta</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kalgi</span> <span property="familyName">Mody</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rodolfo F.</span> <span property="familyName">Perini</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dongyuan</span> <span property="familyName">Xing</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Toni K.</span> <span property="familyName">Choueiri</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the CLEAR Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-31</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">February 13, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">1289</span>-<span property="pageEnd">1300</span></div><div class="doi">DOI: 10.1056/NEJMoa2035716</div><div class="core-enumeration"><a href="/toc/nejm/384/14"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">14</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRobert%2BMotzer%252C%2BBoris%2BAlekseev%252C%2BSun-Young%2BRha%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2035716%26title%3DLenvatinib%2Bplus%2BPembrolizumab%2Bor%2BEverolimus%2Bfor%2BAdvanced%2BRenal%2BCell%2BCarcinoma%26publicationDate%3D04%252F08%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2035716" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRobert%2BMotzer%252C%2BBoris%2BAlekseev%252C%2BSun-Young%2BRha%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2035716%26title%3DLenvatinib%2Bplus%2BPembrolizumab%2Bor%2BEverolimus%2Bfor%2BAdvanced%2BRenal%2BCell%2BCarcinoma%26publicationDate%3D04%252F08%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/0d6fce7d-4b50-45af-82c6-9af313b66d6b/nejmoa2035716.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2035716.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2035716" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035716.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P&lt;0.001) and was longer with lenvatinib plus everolimus than with sunitinib (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P&lt;0.001). Overall survival was longer with lenvatinib plus pembrolizumab than with sunitinib (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P=0.005) but was not longer with lenvatinib plus everolimus than with sunitinib (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P=0.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received lenvatinib plus pembrolizumab, 83.1% of those who received lenvatinib plus everolimus, and 71.8% of those who received sunitinib. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02811861" target="_blank">NCT02811861</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo006000/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006000" data-multimedia-filename="NEJMdo006000_600x400.jpg">
                <img src="/cms/asset/bdd53c5f-8f38-4ac3-923f-f416747217d1/media/NEJMdo006000_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006000" data-multimedia-filename="NEJMdo006000_600x400.jpg">Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">First-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors has been shown to provide benefits for patients with advanced renal cell carcinoma, but most patients have disease relapse as resistance develops.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> Treatment with immune-checkpoint inhibitors, either as a dual-type combination (e.g., nivolumab plus ipilimumab) or in combination with kinase inhibitors (e.g., pembrolizumab or avelumab plus axitinib, or cabozantinib plus nivolumab), has provided better outcomes than sunitinib for patients with metastatic renal cell carcinoma.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r6 r7 r8" id="body-ref-r8" href-manipulated="true">3-8</a></sup> These regimens are now recommended as standard-of-care options,<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10" id="body-ref-r10" href-manipulated="true">9,10</a></sup> and more combination strategies are being explored.</div><div role="paragraph">Lenvatinib, an antiangiogenic agent, and pembrolizumab, an anti–programmed cell death 1 (PD-1) monoclonal antibody, have each shown activity as monotherapies for the treatment of renal cell carcinoma.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12" id="body-ref-r12" href-manipulated="true">11,12</a></sup> As a combination regimen, lenvatinib plus everolimus was shown to be associated with longer progression-free survival than everolimus alone as second-line treatment.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-2" href-manipulated="true" aria-label="Reference 11">11</a></sup> In an initial assessment of results from a phase 1b–2 trial, lenvatinib plus pembrolizumab was shown to have promising antitumor activity in previously treated patients with renal cell carcinoma.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-1" href-manipulated="true" aria-label="Reference 13">13</a></sup> Here, we report the results of A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">We enrolled patients who were 18 years of age or older and had previously untreated advanced renal cell carcinoma with a clear-cell component and at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Other key inclusion criteria were a Karnofsky performance-status score of at least 70 (scores range from 0 to 100, with lower scores indicating greater disability)<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup>; adequately controlled blood pressure, with or without medications; and adequate organ function. Full inclusion and exclusion criteria are described in the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Trial Design and Treatment</h3><div role="paragraph">Patients were randomly assigned in a 1:1:1 ratio to receive treatment with one of three regimens: lenvatinib plus pembrolizumab, lenvatinib plus everolimus, or sunitinib. Randomization was stratified according to geographic region (Western Europe and North America or the rest of the world) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk group (favorable, intermediate, or poor risk)<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> (definitions are included in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). We report the final analysis of progression-free survival.</div><div role="paragraph">In the lenvatinib-plus-pembrolizumab group, lenvatinib was administered at a dose of 20 mg orally once daily for each 21-day treatment cycle, and pembrolizumab was administered at a dose of 200 mg intravenously on day 1 of each 21-day cycle. In the lenvatinib-plus-everolimus group, lenvatinib was administered at a dose of 18 mg and everolimus was administered at a dose of 5 mg orally once daily for each 21-day cycle. Doses for each group were determined on the basis of the results of phase 1 dose-finding trials.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r16 r17" id="body-ref-r17-1" href-manipulated="true">13,16,17</a></sup> Sunitinib was administered at a dose of 50 mg orally once daily for 4 weeks of treatment followed by 2 weeks with no treatment. Full details regarding the approaches used for dose interruptions and dose reductions can be found in the protocol. Details regarding discontinuation of treatment are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-3"><h3>Trial Oversight</h3><div role="paragraph">The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice Guidelines and the principles of the 2013 Declaration of Helsinki. Institutional review boards or independent ethics committees approved the protocol and appropriate related documents; all patients provided written informed consent. Safety and efficacy data were monitored by an independent data and safety monitoring committee.</div><div role="paragraph">The trial was designed by academic authors and authors who were employees of the sponsors. All the authors had full access to the data and attest to their full participation in the development and review of the manuscript for publication. The authors vouch for the fidelity of the trial to the protocol and statistical plan and attest to the accuracy and completeness of the data and analyses. A medical writer funded by the sponsors assisted with the preparation of the manuscript.</div></section><section id="sec-1-4"><h3>End Points and Assessments</h3><div role="paragraph">Progression-free survival and all other response-associated end points were assessed with the use of RECIST, version 1.1. The primary end point was progression-free survival as assessed by an independent review committee. Key secondary end points were overall survival and objective response as assessed by an independent review committee. Other secondary end points included safety and progression-free survival as assessed by the investigators. Key exploratory end points included the duration of response as assessed by an independent review committee and objective response as assessed by the investigators. All subgroup analyses were prespecified in the statistical analysis plan. Data on patient-reported outcomes were collected but are not reported here.</div><div role="paragraph">Tumor assessments (by computed tomography or magnetic resonance imaging) were performed with the use of RECIST, version 1.1, at screening and every 8 weeks from the date of randomization thereafter. Additional details regarding the frequency of bone and brain scans are provided in the protocol.</div><div role="paragraph">For safety assessments, all adverse events and serious adverse events were monitored and recorded with the use of the Common Terminology Criteria for Adverse Events, version 4.03. The adverse events that are summarized and discussed in this report are those that emerged or worsened in severity during treatment (up to 30 days after the last dose of trial drug). Patients also underwent regular monitoring by means of physical examinations and laboratory evaluations for hematologic measures, blood chemical values, and urine values. Vital signs and electrocardiograms were also obtained periodically. Details regarding programmed cell death ligand 1 (PD-L1) testing are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">Sample size was estimated on the basis of the requirements for the progression-free survival analysis, with approximately 1050 patients planned for stratified randomization across groups. The same treatment effect was assumed for the primary comparisons of lenvatinib plus pembrolizumab and lenvatinib plus everolimus with sunitinib. Assumptions of a median progression-free survival of 12.3 months with sunitinib and a hazard ratio for disease progression or death of 0.714 in evaluations of each drug combination as compared with sunitinib would correspond to 40% longer median progression-free survival (i.e., 17.2 months) with each of the two drug combinations. We calculated that power of 90% with a two-sided alpha of 0.045 would be achieved with 388 events of disease progression or death between the lenvatinib-plus-pembrolizumab and sunitinib groups; the power for evaluating lenvatinib plus everolimus as compared with sunitinib at an alpha of 0.0049 was 70%, which would be at least 90% after alpha reallocation from previous rejected tests. Details regarding prespecified interim analyses of progression-free survival, overall survival, and objective response are provided in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">A sequential approach<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> for multiple comparisons was used to adjust for multiplicity and to control the familywise error rate for progression-free survival and overall survival and the percentage of patients with an objective response at the alpha of 0.0499 (two-sided) in comparisons of each combination regimen with sunitinib. All stratified analyses applied the stratification factors used at randomization.</div><div role="paragraph">Efficacy was assessed in the intention-to-treat population, which included all the patients who underwent randomization. Progression-free survival and overall survival were evaluated with Kaplan–Meier estimates and two-sided 95% confidence intervals. Differences between each combination regimen and sunitinib were evaluated with the stratified log-rank test. A stratified Cox regression model with Efron’s method for handling tied results was used to estimate the hazard ratios and 95% confidence intervals. Between-group differences in the percentage of patients with an objective response were evaluated with a stratified Cochran–Mantel–Haenszel test; the stratified relative risk and 95% confidence intervals are provided. The duration of response in patients with a confirmed response was estimated by the Kaplan–Meier method.</div><div role="paragraph">Safety analyses included all the patients who received at least one dose of any trial drug. The full statistical analysis plan is available with the protocol.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients and Treatments</h3><div role="paragraph">Between October 13, 2016, and July 24, 2019, a total of 1417 patients were screened for eligibility, 1069 of whom underwent randomization: 355 were assigned to receive lenvatinib plus pembrolizumab, 357 to receive lenvatinib plus everolimus, and 357 to receive sunitinib (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). The trial involved 200 sites in 20 countries.</div><div role="paragraph">Baseline demographic and disease characteristics of the patients were balanced among the treatment groups (<a href="#t1">Table 1</a>). Data cutoff occurred on August 28, 2020, for the final analysis of progression-free survival, with a median follow-up for overall survival of 26.6 months. At the cutoff date, treatment was ongoing for 40.0% of the patients in the lenvatinib-plus-pembrolizumab group, 31.4% of the patients in the lenvatinib-plus-everolimus group, and 18.8% of the patients in the sunitinib group. The primary reason for treatment discontinuation in any group was disease progression.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/d8f9b074-98dd-4e1d-8ec6-17d2f1ad4acb/assets/images/large/nejmoa2035716_t1.jpg" height="2817" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Lenvatinib plus Pembrolizumab<br>(N=355)</th><th class="txxx-borders">Lenvatinib plus Everolimus<br>(N=357)</th><th class="txxr-borders">Sunitinib<br>(N=357)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">64 (34–88)</td><td class="xxxx-borders shading">62 (32–86)</td><td class="xxxr-borders shading">61 (29–82)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age &lt;65 yr — no. (%)</td><td class="xxxx-borders">194 (54.6)</td><td class="xxxx-borders">201 (56.3)</td><td class="xxxr-borders">225 (63.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Male</td><td class="xxxx-borders">255 (71.8)</td><td class="xxxx-borders">266 (74.5)</td><td class="xxxr-borders">275 (77.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">100 (28.2)</td><td class="xxxx-borders shading">91 (25.5)</td><td class="xxxr-borders shading">82 (23.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Geographic region — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Western Europe or North America</td><td class="xxxx-borders shading">198 (55.8)</td><td class="xxxx-borders shading">200 (56.0)</td><td class="xxxr-borders shading">199 (55.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rest of the world</td><td class="xxxx-borders">157 (44.2)</td><td class="xxxx-borders">157 (44.0)</td><td class="xxxr-borders">158 (44.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Karnofsky performance-status score — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">100–90</td><td class="xxxx-borders">295 (83.1)</td><td class="xxxx-borders">286 (80.1)</td><td class="xxxr-borders">294 (82.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">80–70</td><td class="xxxx-borders shading">60 (16.9)</td><td class="xxxx-borders shading">70 (19.6)</td><td class="xxxr-borders shading">62 (17.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">MSKCC prognostic risk group — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Favorable</td><td class="xxxx-borders shading">96 (27.0)</td><td class="xxxx-borders shading">98 (27.5)</td><td class="xxxr-borders shading">97 (27.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">227 (63.9)</td><td class="xxxx-borders">227 (63.6)</td><td class="xxxr-borders">228 (63.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor</td><td class="xxxx-borders shading">32 (9.0)</td><td class="xxxx-borders shading">32 (9.0)</td><td class="xxxr-borders shading">32 (9.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IMDC prognostic risk group — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Favorable</td><td class="xxxx-borders shading">110 (31.0)</td><td class="xxxx-borders shading">114 (31.9)</td><td class="xxxr-borders shading">124 (34.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">210 (59.2)</td><td class="xxxx-borders">195 (54.6)</td><td class="xxxr-borders">192 (53.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor</td><td class="xxxx-borders shading">33 (9.3)</td><td class="xxxx-borders shading">42 (11.8)</td><td class="xxxr-borders shading">37 (10.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Could not be evaluated</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxr-borders">4 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Sarcomatoid features — no. (%)</td><td class="xxxx-borders shading">28 (7.9)</td><td class="xxxx-borders shading">24 (6.7)</td><td class="xxxr-borders shading">21 (5.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">PD-L1 combined positive score — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥1</td><td class="xxxx-borders shading">107 (30.1)</td><td class="xxxx-borders shading">116 (32.5)</td><td class="xxxr-borders shading">119 (33.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1</td><td class="xxxx-borders">112 (31.5)</td><td class="xxxx-borders">118 (33.1)</td><td class="xxxr-borders">103 (28.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Not available</td><td class="xxxx-borders shading">136 (38.3)</td><td class="xxxx-borders shading">123 (34.5)</td><td class="xxxr-borders shading">135 (37.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of metastatic organs or sites — no. (%)<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">97 (27.3)</td><td class="xxxx-borders shading">125 (35.0)</td><td class="xxxr-borders shading">108 (30.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥2</td><td class="xxxx-borders">254 (71.5)</td><td class="xxxx-borders">229 (64.1)</td><td class="xxxr-borders">246 (68.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Site of metastasis — no. (%)<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lung</td><td class="xxxx-borders">249 (70.1)</td><td class="xxxx-borders">245 (68.6)</td><td class="xxxr-borders">239 (66.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lymph node</td><td class="xxxx-borders shading">170 (47.9)</td><td class="xxxx-borders shading">163 (45.7)</td><td class="xxxr-borders shading">159 (44.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bone</td><td class="xxxx-borders">85 (23.9)</td><td class="xxxx-borders">86 (24.1)</td><td class="xxxr-borders">97 (27.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Liver</td><td class="xxxx-borders shading">60 (16.9)</td><td class="xxxx-borders shading">62 (17.4)</td><td class="xxxr-borders shading">61 (17.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Previous nephrectomy — no. (%)</td><td class="xbxx-borders">262 (73.8)</td><td class="xbxx-borders">260 (72.8)</td><td class="xbxr-borders">275 (77.0)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Percentages may not total 100 because of rounding. One patient in the lenvatinib-plus-pembrolizumab group had carcinoma without a clear-cell component.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability. Scores were missing for 1 patient each in the lenvatinib-plus-everolimus and sunitinib groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">A Memorial Sloan Kettering Cancer Center (MSKCC) score of 0 indicates favorable risk, a score of 1 or 2 intermediate risk, and a score of 3 or higher poor risk. MSKCC scores are defined in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score of 0 indicates favorable risk, a score of 1 or 2 intermediate risk, and a score of 3 to 6 poor risk. IMDC scores are defined in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Programmed cell death ligand 1 (PD-L1) expression was assessed with the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) and reported as the combined positive score, defined as the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Kidney was not included in the number of metastatic organs or sites. The only tumor location was in the kidney for 3 patients (0.8%) in the lenvatinib-plus-everolimus group, 4 patients (1.1%) in the lenvatinib-plus-pembrolizumab group, and 3 patients (0.8%) in the sunitinib group.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Four common sites of metastasis are shown. Patients may have had metastasis at more than one site.</div></div></div></figcaption></figure></div><div role="paragraph">Among patients who discontinued therapy, 54.9% in the lenvatinib-plus-pembrolizumab group, 68.2% in the lenvatinib-plus-everolimus group, and 71.0% in the sunitinib group received subsequent systemic therapy during follow-up (Table S1 in the <a href="#ap2">Supplementary Appendix</a>). Antiangiogenic therapy was the most common therapy received after treatment with lenvatinib plus pembrolizumab (in 50.7% of patients), whereas PD-1–PD-L1 checkpoint inhibitor therapy was the most commonly received therapy after lenvatinib plus everolimus (51.4%) or sunitinib (53.1%).</div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Progression-free survival as determined by an independent review committee was significantly longer in the lenvatinib-plus-pembrolizumab group than in the sunitinib group (median, 23.9 months [95% confidence interval {CI}, 20.8 to 27.7] vs. 9.2 months [95% CI, 6.0 to 11.0]; hazard ratio for disease progression or death, 0.39; 95% CI, 0.32 to 0.49; P&lt;0.001) and was significantly longer in the lenvatinib-plus-everolimus group than in the sunitinib group (median, 14.7 months [95% CI, 11.1 to 16.7] vs. 9.2 months [95% CI, 6.0 to 11.0]; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P&lt;0.001) (<a href="#f1">Figure 1A</a>). Progression-free survival as assessed by the investigators was also longer with lenvatinib plus pembrolizumab than with sunitinib (median, 22.1 months [95% CI, 17.1 to 26.9] vs. 9.5 months [95% CI, 7.9 to 11.1]; hazard ratio, 0.47; 95% CI, 0.38 to 0.58) and longer with lenvatinib plus everolimus than with sunitinib (median, 14.6 months [95% CI, 11.2 to 18.0] vs. 9.5 months [95% CI, 7.9 to 11.1]; hazard ratio, 0.70; 95% CI, 0.57 to 0.85) (Fig. S2). The results for progression-free survival favored the two combination regimens over sunitinib across all evaluated subgroups, including those based on MSKCC prognostic risk group and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group (<a href="#f1">Figures 1B</a> and S3).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f1.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/67b0cb54-4861-4465-8bb4-e241e025fc50/assets/images/large/nejmoa2035716_f1.jpg" height="3065" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Panel A shows the Kaplan–Meier curves for progression-free survival in each treatment group. Tick marks indicate censored data. Panel B shows the analysis of progression-free survival in subgroups of patients in the lenvatinib-plus-pembrolizumab group and the sunitinib group. Progression-free survival was assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent review committee. Differences between the treatment groups were evaluated with the stratified log-rank test, stratified according to geographic region and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk group. A stratified Cox regression model was used to estimate the hazard ratio for disease progression or death and 95% confidence intervals (CIs). MSKCC and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups are defined in the <a href="#ap2">Supplementary Appendix</a>. Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability. The programmed cell death ligand 1 (PD-L1) combined positive score is defined as the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100.</div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">In the analysis of overall survival, 79.2% of the patients in the lenvatinib-plus-pembrolizumab group, 66.1% of the patients in the lenvatinib-plus-everolimus group, and 70.4% of the patients in the sunitinib group were alive at 24 months. Median overall survival was not reached with any treatment; survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P=0.005) (<a href="#f2">Figure 2A</a>). Overall survival with lenvatinib plus everolimus was not significantly longer than that with sunitinib (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P=0.30) (<a href="#f2">Figure 2A</a>).</span> Subgroup analyses of overall survival according to baseline characteristics are shown in Fig. S4. The hazard ratio for overall survival favored lenvatinib plus pembrolizumab over sunitinib in most subgroups, including patients with PD-L1–positive or –negative tumors, with an exception observed in patients with favorable risk features as defined by IMDC criteria.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f2.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/99e0f0f6-c8fb-4199-8345-a60705f5486a/assets/images/large/nejmoa2035716_f2.jpg" height="2280" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival and Duration of Response.</div><div class="notes"><div role="doc-footnote">Panel A shows the Kaplan–Meier curves for overall survival, and Panel B shows the Kaplan–Meier curves for the duration of response in patients who had a response. Tick marks indicate censored data. NE denotes could not be estimated, and NR not reached.</div></div></figcaption></figure></div><div role="paragraph">The percentage of patients with a confirmed objective response to treatment as determined by an independent review committee with the use of RECIST, version 1.1, was 71.0% with lenvatinib plus pembrolizumab, 53.5% with lenvatinib plus everolimus, and 36.1% with sunitinib (relative risk with lenvatinib plus pembrolizumab vs. sunitinib, 1.97 [95% CI, 1.69 to 2.29]; and with lenvatinib plus everolimus vs. sunitinib, 1.48 [95% CI, 1.26 to 1.74]) (<a href="#t2">Table 2</a>). The percentage of patients with a complete response was 16.1% in the lenvatinib-plus-pembrolizumab group, 9.8% in the lenvatinib-plus-everolimus group, and 4.2% in the sunitinib group (<a href="#t2">Table 2</a>). The median duration of response in patients who had a confirmed response was 25.8 months (95% CI, 22.1 to 27.9) in the lenvatinib-plus-pembrolizumab group, 16.6 months (95% CI, 14.6 to 20.6) in the lenvatinib-plus-everolimus group, and 14.6 months (95% CI, 9.4 to 16.7) in the sunitinib group (<a href="#t2">Table 2</a> and <a href="#f2">Figure 2B</a>). The results for objective response as assessed by the investigators was consistent with those for objective response as assessed by the independent review committee (Table S2).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/fdf0f359-b94c-49c1-806d-4a73d64db39c/assets/images/large/nejmoa2035716_t2.jpg" height="1171" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Measure</th><th class="txxx-borders">Lenvatinib plus Pembrolizumab<br>(N=355)</th><th class="txxx-borders">Lenvatinib plus Everolimus<br>(N=357)</th><th class="txxr-borders">Sunitinib<br>(N=357)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Objective response (95% CI) — %<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">71.0 (66.3–75.7)</td><td class="xxxx-borders shading">53.5 (48.3–58.7)</td><td class="xxxr-borders shading">36.1 (31.2–41.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relative risk vs. sunitinib (95% CI)</td><td class="xxxx-borders">1.97 (1.69–2.29)</td><td class="xxxx-borders">1.48 (1.26–1.74)</td><td class="xxxr-borders">Reference</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Best overall response — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response</td><td class="xxxx-borders">57 (16.1)</td><td class="xxxx-borders">35 (9.8)</td><td class="xxxr-borders">15 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response</td><td class="xxxx-borders shading">195 (54.9)</td><td class="xxxx-borders shading">156 (43.7)</td><td class="xxxr-borders shading">114 (31.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable disease</td><td class="xxxx-borders">68 (19.2)</td><td class="xxxx-borders">120 (33.6)</td><td class="xxxr-borders">136 (38.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive disease</td><td class="xxxx-borders shading">19 (5.4)</td><td class="xxxx-borders shading">26 (7.3)</td><td class="xxxr-borders shading">50 (14.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unknown or could not be evaluated<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">16 (4.5)</td><td class="xxxx-borders">20 (5.6)</td><td class="xxxr-borders">42 (11.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to response (range) — mo</td><td class="xxxx-borders shading">1.94 (1.41–18.50)</td><td class="xxxx-borders shading">1.91 (1.41–14.36)</td><td class="xxxr-borders shading">1.94 (1.61–16.62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xbxx-borders">25.8 (22.1–27.9)</td><td class="xbxx-borders">16.6 (14.6–20.6)</td><td class="xbxr-borders">14.6 (9.4–16.7)</td></tr></tbody></table></div><figcaption><div class="caption">Confirmed Tumor Responses.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Responses were assessed by an independent review committee with Response Evaluation Criteria in Solid Tumors, version 1.1. Percentages may not total 100 due to rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Additional details of the statistical analysis and the results of interim analysis 2 (a prespecified interim analysis that had been planned as the final analysis of objective response) are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The best overall response was unknown or could not be evaluated for patients who had no baseline or no postbaseline tumor assessments, at least one lesion that could not be evaluated, or early stable disease (occurring &lt;7 weeks after randomization).</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Exposure and Safety</h3><div role="paragraph">The median duration of treatment was 17.0 months (range, 0.1 to 39.1) in the lenvatinib-plus-pembrolizumab group, 11.0 months (range, 0.1 to 40.0) in the lenvatinib-plus-everolimus group, and 7.8 months (range, 0.1 to 37.0) in the sunitinib group. The median relative dose intensity of lenvatinib per patient was 69.6% (range, 12.6 to 157.1) in the lenvatinib-plus-pembrolizumab group and 70.4% (range, 22.9 to 100.0) in the lenvatinib-plus-everolimus group. The median relative dose intensity of everolimus per patient was 89.3% (range, 27.6 to 100.0) in the lenvatinib-plus-everolimus group. The median number of infusions of pembrolizumab per patient was 22 (range, 1 to 39). The median relative dose intensity of sunitinib was 83.2% (range, 18.8 to 100.0).</div><div role="paragraph"><a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">Almost all patients in each group had adverse events (of any cause) that emerged or worsened during treatment (99.7% of the patients in both the lenvatinib-plus-pembrolizumab group and the lenvatinib-plus-everolimus group and 98.5% of the patients in the sunitinib group), with diarrhea being the most common event in each group (in 61.4% of the patients in the lenvatinib-plus-pembrolizumab group, in 66.5% of those in the lenvatinib-plus-everolimus group, and in 49.4% of those in the sunitinib group) (<a href="#t3">Table 3</a> and S3).</span> Grade 3 or higher adverse events of any cause occurred in 82.4% of the patients who received lenvatinib plus pembrolizumab, in 83.1% of the patients who received lenvatinib plus everolimus, and in 71.8% of the patients who received sunitinib. Grade 3 or higher adverse events that occurred in 10% or more of patients in any treatment group included diarrhea, hypertension, an elevated lipase level, and hypertriglyceridemia.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/e358eb5a-f753-4c39-b6c2-2496415d077e/assets/images/large/nejmoa2035716_t3.jpg" height="2029" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Lenvatinib plus Pembrolizumab<br>(N=352)</span></th><th class="txxx-borders" colspan="2"><span>Lenvatinib plus Everolimus<br>(N=355)</span></th><th class="txxr-borders" colspan="2"><span>Sunitinib<br>(N=340)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade ≥3<a href="#t3fn2" role="doc-noteref">†</a></th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade ≥3<a href="#t3fn2" role="doc-noteref">†</a></th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade ≥3<a href="#t3fn2" role="doc-noteref">†</a></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any event</td><td class="xxxx-borders shading">351 (99.7)</td><td class="xxxx-borders shading">290 (82.4)</td><td class="xxxx-borders shading">354 (99.7)</td><td class="xxxx-borders shading">295 (83.1)</td><td class="xxxx-borders shading">335 (98.5)</td><td class="xxxr-borders shading">244 (71.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">216 (61.4)</td><td class="xxxx-borders">34 (9.7)</td><td class="xxxx-borders">236 (66.5)</td><td class="xxxx-borders">41 (11.5)</td><td class="xxxx-borders">168 (49.4)</td><td class="xxxr-borders">18 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">195 (55.4)</td><td class="xxxx-borders shading">97 (27.6)</td><td class="xxxx-borders shading">162 (45.6)</td><td class="xxxx-borders shading">80 (22.5)</td><td class="xxxx-borders shading">141 (41.5)</td><td class="xxxr-borders shading">64 (18.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hypothyroidism<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">166 (47.2)</td><td class="xxxx-borders">5 (1.4)</td><td class="xxxx-borders">95 (26.8)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">90 (26.5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">142 (40.3)</td><td class="xxxx-borders shading">14 (4.0)</td><td class="xxxx-borders shading">144 (40.6)</td><td class="xxxx-borders shading">22 (6.2)</td><td class="xxxx-borders shading">105 (30.9)</td><td class="xxxr-borders shading">5 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">141 (40.1)</td><td class="xxxx-borders">15 (4.3)</td><td class="xxxx-borders">149 (42.0)</td><td class="xxxx-borders">27 (7.6)</td><td class="xxxx-borders">125 (36.8)</td><td class="xxxr-borders">15 (4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">126 (35.8)</td><td class="xxxx-borders shading">9 (2.6)</td><td class="xxxx-borders shading">141 (39.7)</td><td class="xxxx-borders shading">9 (2.5)</td><td class="xxxx-borders shading">113 (33.2)</td><td class="xxxr-borders shading">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Stomatitis</td><td class="xxxx-borders">122 (34.7)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxx-borders">169 (47.6)</td><td class="xxxx-borders">22 (6.2)</td><td class="xxxx-borders">131 (38.5)</td><td class="xxxr-borders">7 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Dysphonia</td><td class="xxxx-borders shading">105 (29.8)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">84 (23.7)</td><td class="xxxx-borders shading">2 (0.6)</td><td class="xxxx-borders shading">14 (4.1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Weight decrease</td><td class="xxxx-borders">105 (29.8)</td><td class="xxxx-borders">28 (8.0)</td><td class="xxxx-borders">116 (32.7)</td><td class="xxxx-borders">26 (7.3)</td><td class="xxxx-borders">31 (9.1)</td><td class="xxxr-borders">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Proteinuria</td><td class="xxxx-borders shading">104 (29.5)</td><td class="xxxx-borders shading">27 (7.7)</td><td class="xxxx-borders shading">121 (34.1)</td><td class="xxxx-borders shading">29 (8.2)</td><td class="xxxx-borders shading">43 (12.6)</td><td class="xxxr-borders shading">10 (2.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Palmar–plantar erythrodysesthesia syndrome</td><td class="xxxx-borders">101 (28.7)</td><td class="xxxx-borders">14 (4.0)</td><td class="xxxx-borders">81 (22.8)</td><td class="xxxx-borders">10 (2.8)</td><td class="xxxx-borders">127 (37.4)</td><td class="xxxr-borders">13 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Arthralgia</td><td class="xxxx-borders shading">99 (28.1)</td><td class="xxxx-borders shading">5 (1.4)</td><td class="xxxx-borders shading">76 (21.4)</td><td class="xxxx-borders shading">5 (1.4)</td><td class="xxxx-borders shading">52 (15.3)</td><td class="xxxr-borders shading">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rash</td><td class="xxxx-borders">96 (27.3)</td><td class="xxxx-borders">13 (3.7)</td><td class="xxxx-borders">88 (24.8)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">47 (13.8)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">92 (26.1)</td><td class="xxxx-borders shading">12 (3.4)</td><td class="xxxx-borders shading">113 (31.8)</td><td class="xxxx-borders shading">10 (2.8)</td><td class="xxxx-borders shading">68 (20.0)</td><td class="xxxr-borders shading">5 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">89 (25.3)</td><td class="xxxx-borders">3 (0.9)</td><td class="xxxx-borders">73 (20.6)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">64 (18.8)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Dysgeusia</td><td class="xbxx-borders shading">43 (12.2)</td><td class="xbxx-borders shading">1 (0.3)</td><td class="xbxx-borders shading">59 (16.6)</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">95 (27.9)</td><td class="xbxr-borders shading">1 (0.3)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events of Any Cause That Emerged or Worsened during Treatment in at Least 25% of the Patients in Any Treatment Group.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Safety assessments were based on as-treated principle and consisted of monitoring and recording all adverse events and serious adverse events with the use of the Common Terminology Criteria for Adverse Events, version 4.03, in the group of patients who received at least one dose of trial drug. Events are listed in descending order of frequency in the lenvatinib-plus-pembrolizumab group. Adverse events were coded to the <i>Medical Dictionary for Regulatory Activities</i>, version 21.1 or higher, lower-level term closest to the verbatim term.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Of the 15 patients in the lenvatinib-plus-pembrolizumab group who had grade 5 adverse events during treatment, 11 had fatal events not attributed to disease progression (acute renal failure, uncontrolled hypertension, complications from myasthenic syndrome, complications from autoimmune hepatitis, cardiac arrest, and death–cause not specified in 1 patient each; hemorrhagic events in 2 patients; and sepsis in 3 patients). In the lenvatinib-plus-everolimus group, of the 22 patients with grade 5 adverse events, 10 had fatal events not attributed to disease progression (pneumonia, urosepsis, colon perforation, fistula, infection, and pneumothorax in 1 patient each; hemorrhagic events and death–cause not specified in 2 patients each). Among the 11 patients in the sunitinib group with grade 5 adverse events during treatment, fatal events not attributed to disease progression occurred in 2 patients (respiratory failure and acute kidney injury in 1 patient and death–cause not specified in 1 patient).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Hypothyroidism is an adverse event of interest associated with pembrolizumab; additional information regarding adverse events of interest is provided in the <a href="#ap2">Supplementary Appendix</a>. Information regarding these adverse events was not collected specifically as “immune-related,” in order to preserve blinding.</div></div></div></figcaption></figure></div><div role="paragraph">In the lenvatinib-plus-pembrolizumab group, adverse events of any grade led to discontinuation of lenvatinib, pembrolizumab, or both drugs in 37.2% of patients (lenvatinib, 25.6%; pembrolizumab, 28.7%; both drugs, 13.4%); led to dose reduction of lenvatinib in 68.8% of patients; and led to interruption of lenvatinib, pembrolizumab, or both drugs in 78.4% of patients. In the lenvatinib-plus-everolimus group, adverse events of any grade led to discontinuation of lenvatinib, everolimus, or both drugs in 27.0% of patients (lenvatinib, 22.0%; everolimus, 24.8%; both drugs, 18.9%); led to dose reduction of lenvatinib, everolimus, or both drugs in 73.2% patients; and led to interruption of lenvatinib, everolimus, or both drugs in 83.4% of patients. In the sunitinib group, adverse events of any grade led to discontinuation of sunitinib in 14.4% patients, led to dose reduction in 50.3% patients, and led to treatment interruption in 53.8% patients. The median time to discontinuation due to adverse events was 8.97 months in the lenvatinib-plus-pembrolizumab group, 5.49 months in the lenvatinib-plus-everolimus group, and 4.57 months in the sunitinib group.</div><div role="paragraph">Adverse events that were frequently judged by the investigators to be related to the trial treatment across the treatment groups included diarrhea and hypertension (Table S4). Adverse events of interest that were associated with pembrolizumab and everolimus, as well as clinically significant adverse events that emerged or worsened during treatment with lenvatinib, are described in Tables S5 through S7.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this phase 3 trial involving patients with advanced renal cell carcinoma, we evaluated two regimens as first-line treatment — lenvatinib plus pembrolizumab and lenvatinib plus everolimus — as compared with the standard of care, sunitinib. Progression-free survival, the primary end point, was significantly longer among patients treated with either lenvatinib plus pembrolizumab or lenvatinib plus everolimus than among those treated with sunitinib. Treatment with lenvatinib plus pembrolizumab was also associated with significantly longer overall survival than sunitinib. However, treatment with lenvatinib plus everolimus did not have a significantly greater effect on overall survival than sunitinib. The efficacy outcomes as evaluated by the independent review committee were consistent with those evaluated by the investigators, across all therapies. Moreover, the results for progression-free and overall survival favored lenvatinib plus pembrolizumab over sunitinib in most evaluated subgroups.</div><div role="paragraph">The safety profile of each combination therapy was consistent with that of each component as a single agent, as well as with the previously reported safety profiles for each combination.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r13 r17 r19 r20 r21" id="body-ref-r21" href-manipulated="true">11,13,17,19–21</a></sup> Adverse events that emerged or worsened during treatment resulted in dose reduction of lenvatinib in 68.8% of patients in the lenvatinib-plus-pembrolizumab group and dose reduction of lenvatinib, everolimus, or both drugs in 73.2% of patients in the lenvatinib-plus-everolimus group. Interruption or dose reduction of lenvatinib after initiation of treatment is a common strategy (irrespective of indication) to maximize therapeutic benefit while reducing the risk of toxic effects. Overall, interruptions and reductions were effectively used in this trial, which allowed patients to continue to receive life-prolonging therapy for a longer period. Although the combination of lenvatinib and pembrolizumab was associated with some notable side effects, these adverse events are often adequately managed with medical therapy if they are diagnosed early during patient visits. Of note, adverse events associated with lenvatinib plus pembrolizumab were likely to have been influenced by the longer treatment duration in this group than in the sunitinib group.</div><div role="paragraph">Although caution should be used when comparing trials, in this trial, the median progression-free survival in the lenvatinib-plus-pembrolizumab group (23.9 months), along with the percentage of patients in that group who had an objective response (71.0%) — and especially the 16.1% of patients who had a complete response — were notable relative to findings in other pivotal first-line trials in advanced renal cell carcinoma, including recent trials of immune-checkpoint inhibitor–containing regimens.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r6 r22" id="body-ref-r22-1" href-manipulated="true">3–6,22</a></sup> Moreover, the percentage of patients alive at 24 months in the lenvatinib-plus-pembrolizumab group (79.2%) was noteworthy in the context of other immune-checkpoint inhibitor–containing regimens.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r6 r22" id="body-ref-r22-2" href-manipulated="true">3–6,22</a></sup></div><div role="paragraph">Progression-free survival was significantly longer with lenvatinib plus everolimus than with sunitinib; however, only lenvatinib plus pembrolizumab showed a benefit for overall survival as compared with sunitinib. The finding of an overall survival benefit of lenvatinib in combination with pembrolizumab but not in combination with everolimus confirms that an immune-checkpoint inhibitor–kinase inhibitor combination therapy is important in the first-line treatment of patients with advanced renal cell carcinoma.</div><div role="paragraph">A limitation of this trial was that patients and investigators were aware of the treatment-group assignments. In addition, different percentages of patients with known prognostic risk features, including poor IMDC risk and sarcomatoid histologic features, should be considered in cross-trial comparisons. Although data on patient-reported outcomes were collected, the analysis is not yet available. Longer follow-up in this trial would also help to better define the long-term efficacy of these combination regimens.</div><div role="paragraph">Our trial showed that combination therapy with lenvatinib plus pembrolizumab provided significantly greater benefits than sunitinib with regard to progression-free survival and overall survival in the first-line treatment of patients with advanced renal cell carcinoma. Grade 3 or higher adverse events occurring in 10% or more of patients in any group included hypertension, diarrhea, and generally asymptomatic elevations in lipase levels. The safety profile of lenvatinib plus pembrolizumab was consistent with the known profile of each drug.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on February 13, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Eisai</span> and <span class="named-content" data-type="funder">Merck Sharp and Dohme</span>. The conduct of the trial at the Memorial Sloan Kettering Cancer Center was supported in part by a Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).</div><div role="paragraph">Dr. Motzer reports receiving grant support, paid to his institution, and consulting fees from Pfizer, Novartis, Genentech, and Roche, consulting fees from Exelixis, Incyte, Eli Lilly, AstraZeneca, and EMD Serono, and grant support, paid to his institution, and travel support from Bristol-Myers Squibb (BMS); Dr. Alekseev, receiving grant support, consulting fees, fees for serving on a speakers bureau, and travel support from AstraZeneca, Bayer, BMS, Ferring, Janssen, Sanofi, Pfizer, Astellas Pharma, Merck Sharp and Dohme (MSD), Eisai, and Ipsen, grant support, consulting fees, and fees for serving on a speakers bureau from Merck, and grant support from Bavarian Nordic; Dr. Rha, receiving consulting fees and steering committee fees from Eisai, consulting fees, advisory board fees, and provision of drugs from MSD, consulting fees and advisory board fees from Daiichi Sankyo and Eli Lilly, and provision of drugs from Celltrion, Boehringer Ingelheim, BMS, Incyte, and Aslan Pharmaceuticals; Dr. Porta, receiving consulting fees and lecture fees from MSD and Ipsen, consulting fees, lecture fees, and steering committee fees from Eisai and BMS, consulting fees from AstraZeneca, Merck, and Angelini Pharma, consulting fees, lecture fees, steering committee fees and fees for expert testimony from Pfizer and EUSA Pharma, lecture fees from Novartis and General Electrics, and travel support from Roche; Dr. Eto, receiving lecture fees and advisory board fees from Eisai, Novartis, BMS, and Merck and grant support, lecture fees, and advisory board fees from MSD, Ono Pharmaceutical, and Pfizer; Dr. Powles, receiving grant support, advisory board fees, lecture fees, consulting fees, and travel support from AstraZeneca, Ipsen, MSD, Pfizer, and Roche, grant support, advisory board fees, lecture fees, and consulting fees from BMS, Exelixis, Merck, Novartis, Seattle Genetics, Astellas Pharma, Johnson &amp; Johnson, and Eisai, and advisory board fees, lecture fees, and consulting fees from Incyte and Merck Serono; Dr. Grünwald, receiving grant support, lecture fees, consulting fees, and travel support from AstraZeneca, BMS, Ipsen, and Pfizer, consulting fees and travel support from Bayer, grant support, lecture fees, and consulting fees from MSD, consulting fees from Roche, Eli Lilly, Onkowissen, and EUSA Pharma, consulting fees and lecture fees from Janssen–Cilag, PharmaMar, Merck Serono, and Eisai, lecture fees from Asklepios Clinic, Diakonie Clinic, Dortmund Hospital, and Clinic of Oldenburg, and grant support and consulting fees from Novartis; Dr. Hutson, receiving grant support, advisory board fees, and fees for serving on a speakers bureau from Eisai, Merck, Pfizer, Exelixis, Astellas Pharma, Janssen, and AVEO Pharmaceuticals; Dr. Méndez-Vidal, receiving lecture fees and travel support from Pfizer, advisory board fees, lecture fees, and travel support from Ipsen, advisory board fees from Eisai, lecture fees from Novartis and MSD, and lecture fees and advisory board fees from Roche; Dr. Alyasova, receiving grant support and consulting fees from Eisai; Dr. Alonso-Gordoa, receiving grant support, lecture fees, and advisory board fees from Ipsen, grant support, consulting fees, and lecture fees from Pfizer, grant support and consulting fees from Roche, lecture fees from Eisai, lecture fees and advisory board fees from Janssen, advisory board fees from Astellas Pharma, Bayer, Sanofi Genzyme, and BMS, and consulting fees from Merck; Dr. Merchan, receiving advisory board fees from Exelixis, grant support, advisory board fees, and fees for serving as principal investigator from Merck, and grant support from Peloton Therapeutics, Genentech, Sillagen, Vyriad, Trishula Therapeutics, Seattle Genetics, Corvus Pharmaceuticals, Eli Lilly, Novartis, and Rubius Therapeutics; Dr. Winquist, receiving grant support and advisory board fees from Eisai and advisory board fees from Merck and Roche; Dr. Maroto, receiving advisory board fees from Pfizer, Ipsen, and BMS; Dr. Goh, receiving fees for serving on a speakers bureau from MSD and advisory board fees and fees for serving on a speakers bureau from BMS; Dr. Kim, receiving consulting fees from MSD and lecture fees from Ipsen, BMS, Sanofi, Janssen, Roche, Merck, Astellas Pharma, and AstraZeneca; Dr. Gurney, receiving advisory board fees from BMS, Pfizer, AstraZeneca, Merck Serono, and MSD and lecture fees from Ipsen; Dr. Peer, receiving consulting fees and lecture fees from MSD, BMS, Eisai, Roche, Bayer, AstraZeneca, Medison, and Pfizer; Dr. Procopio, receiving grant support and advisory fees from AstraZeneca and Ipsen, advisory fees from Bayer, BMS, Janssen, Merck, MSD, and Pfizer, and consulting fees from Novartis; Dr. Melichar, receiving lecture fees, advisory fees, and travel support from MSD, BMS, and Merck Serono and lecture fees and advisory fees from Eisai, Roche, Pfizer, Astellas Pharma, Novartis, Bayer, Sanofi, Servier, AstraZeneca, Pierre Fabre, Amgen, Janssen, and Eli Lilly; Dr. Rolland, receiving advisory fees from Pfizer, BMS, Ipsen, and Merck and travel support from MSD Oncology; Dr. De Giorgi, receiving advisory board fees and travel support from Janssen, lecture fees and advisory board fees from Astellas Pharma, grant support, paid to his institution, and advisory board fees from Sanofi, advisory board fees from Bayer, Novartis, MSD, and PharmaMar, lecture fees and travel support from Pfizer, lecture fees, advisory board fees, and travel support from BMS and Ipsen, grant support, paid to his institution, and travel support from Roche, and grant support, paid to his institution, from AstraZeneca; Dr. Bedke, receiving grant support, paid to his institution, and advisory board fees from AstraZeneca, Astellas Pharma, Eisai, and Novartis, grant support, paid to his institution, advisory board fees, and lecture fees from BMS, Ipsen, MSD, Pfizer, and Roche, advisory board fees from Eusa Pharma, advisory board fees and lecture fees from Merck Serono and Janssen, and grant support, paid to his institution, from Nektar and Seattle Genetics; Dr. Schmidinger, receiving advisory board fees from Pfizer, Exelixis, Merck, and Alkermes and advisory board fees and lecture fees from Ipsen, Eisai, BMS, and MSD; Dr. Dutcus, being employed by Eisai; Dr. Smith, being employed by Eisai; Dr. Dutta, being employed by Eisai; Dr. Perini, being employed by and owning stock in Merck; and Dr. Choueiri, receiving grant support, advisory board fees, consulting fees, fees for manuscript preparation, and travel support from Merck, BMS, Exelixis, AstraZeneca, Eli Lilly, Eisai, Novartis, GSK, Pfizer, and EMD Serono, owning stock in Pionyr Immunotherapeutics and Tempest Therapeutics, and holding pending patent PCT/US2018/12209 (62/445,094) on PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response and pending patent PCT/US2018/058430 (62/581,175) on Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank all the patients and the investigators and their teams who participated in the trial; and Swati Khare, Ph.D., of Oxford PharmaGenesis, for medical writing assistance with an earlier version of the manuscript (paid for by the sponsors).</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2035716_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035716/suppl_file/nejmoa2035716_protocol.pdf" download="nejmoa2035716_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035716_protocol.pdf" data-doi="10.1056/NEJMoa2035716">Download</a></li><li>7.77 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2035716_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035716/suppl_file/nejmoa2035716_appendix.pdf" download="nejmoa2035716_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035716_appendix.pdf" data-doi="10.1056/NEJMoa2035716">Download</a></li><li>1.06 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2035716_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035716/suppl_file/nejmoa2035716_disclosures.pdf" download="nejmoa2035716_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035716_disclosures.pdf" data-doi="10.1056/NEJMoa2035716">Download</a></li><li>719.32 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2035716_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035716/suppl_file/nejmoa2035716_data-sharing.pdf" download="nejmoa2035716_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035716_data-sharing.pdf" data-doi="10.1056/NEJMoa2035716">Download</a></li><li>69.32 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. <em>N Engl J Med</em> 2017;376:354-366.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMra1601333&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28121507/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393111600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+therapy+for+metastatic+renal-cell+carcinoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=354-366&amp;doi=10.1056%2FNEJMra1601333&amp;pmid=28121507" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. <em>Nat Med</em> 2020;26:1519-1530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-020-1093-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33020645/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000575801100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+the+HIF2-VEGF+axis+in+renal+cell+carcinoma.&amp;publication_year=2020&amp;journal=Nat+Med&amp;pages=1519-1530&amp;doi=10.1038%2Fs41591-020-1093-z&amp;pmid=33020645" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Choueiri TK, Powles T, Burotto M, et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. <em>Ann Oncol</em> 2020;31:Suppl 4:S1159-S1159. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2020.08.2257" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000573469102655" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+%2B+cabozantinib+vs+sunitinib+in+first-line+treatment+for+advanced+renal+cell+carcinoma%3A+first+results+from+the+randomized+phase+III+CheckMate+9ER+trial&amp;publication_year=2020&amp;journal=Ann+Oncol&amp;pages=S1159-S1159&amp;doi=10.1016%2Fj.annonc.2020.08.2257" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. <em>N Engl J Med</em> 2018;378:1277-1290.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMoa1712126&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29562145/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429105700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+versus+sunitinib+in+advanced+renal-cell+carcinoma.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=1277-1290&amp;doi=10.1056%2FNEJMoa1712126&amp;pmid=29562145" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <em>N Engl J Med</em> 2019;380:1103-1115.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMoa1816047&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30779531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461898400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab+plus+axitinib+versus+sunitinib+for+advanced+renal-cell+carcinoma.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1103-1115&amp;doi=10.1056%2FNEJMoa1816047&amp;pmid=30779531" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <em>N Engl J Med</em> 2019;380:1116-1127.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMoa1816714&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30779529/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461898400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+axitinib+versus+sunitinib+for+advanced+renal-cell+carcinoma.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1116-1127&amp;doi=10.1056%2FNEJMoa1816714&amp;pmid=30779529" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. <em>Ther Adv Med Oncol</em> 2020;12:1758835920907504-1758835920907504.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1758835920907504" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32215057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000524681900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tyrosine+kinase+inhibitors+and+immunotherapy+combinations+in+renal+cell+carcinoma.&amp;publication_year=2020&amp;journal=Ther+Adv+Med+Oncol&amp;pages=1758835920907504-1758835920907504&amp;doi=10.1177%2F1758835920907504&amp;pmid=32215057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">McKay RR, Bossé D, Choueiri TK. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma. <em>J Clin Oncol</em> 2018 October 29 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.79.0253" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30372392/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453684800013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evolving+systemic+treatment+landscape+for+patients+with+advanced+renal+cell+carcinoma.&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;doi=10.1200%2FJCO.2018.79.0253&amp;pmid=30372392" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines insights: kidney cancer, version 1.2021. <em>J Natl Compr Canc Netw</em> 2020;18:1160-1170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.6004/jnccn.2020.0043" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32886895/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577833900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=NCCN+Guidelines+insights%3A+kidney+cancer%2C+version+1.2021.&amp;publication_year=2020&amp;journal=J+Natl+Compr+Canc+Netw&amp;pages=1160-1170&amp;doi=10.6004%2Fjnccn.2020.0043&amp;pmid=32886895" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Bedke J, Albiges L, Capitanio U, et al. Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. <em>Eur Urol</em> 2020 December 20 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33357997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000694859600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+European+Association+of+Urology+guidelines+on+renal+cell+carcinoma%3A+nivolumab+plus+cabozantinib+joins+immune+checkpoint+inhibition+combination+therapies+for+treatment-na%C3%AFve+metastatic+clear-cell+renal+cell+carcinoma.&amp;publication_year=2020&amp;journal=Eur+Urol&amp;pmid=33357997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <em>Lancet Oncol</em> 2015;16:1473-1482.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(15)00290-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26482279/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000364470900030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvatinib%2C+everolimus%2C+and+the+combination+in+patients+with+metastatic+renal+cell+carcinoma%3A+a+randomised%2C+phase+2%2C+open-label%2C+multicentre+trial.&amp;publication_year=2015&amp;journal=Lancet+Oncol&amp;pages=1473-1482&amp;doi=10.1016%2FS1470-2045%2815%2900290-9&amp;pmid=26482279" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] everolimus alone as second-line treatment. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] safety profiles for each combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Lee J-L, Ziobro M, Suarez C, et al. First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): updated follow-up for KEYNOTE-427 cohort B. <em>J Clin Oncol</em> 2020;38:Suppl:5034-5034. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2020.38.15_suppl.5034" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+pembrolizumab+%28pembro%29+monotherapy+in+advanced+non-clear+cell+renal+cell+carcinoma+%28nccRCC%29%3A+updated+follow-up+for+KEYNOTE-427+cohort+B.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=5034-5034&amp;doi=10.1200%2FJCO.2020.38.15_suppl.5034" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Taylor MH, Lee C-H, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. <em>J Clin Oncol</em> 2020;38:1154-1163.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.01598" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31961766/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000526811600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+IB%2FII+trial+of+lenvatinib+plus+pembrolizumab+in+patients+with+advanced+renal+cell+carcinoma%2C+endometrial+cancer%2C+and+other+selected+advanced+solid+tumors.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=1154-1163&amp;doi=10.1200%2FJCO.19.01598&amp;pmid=31961766" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] treated patients with renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the results of phase 1 dose-finding trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] safety profiles for each combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. <em>J Clin Oncol</em> 1984;2:187-193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.1984.2.3.187" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6699671/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1984SG68700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Karnofsky+performance+status+revisited%3A+reliability%2C+validity%2C+and+guidelines.&amp;publication_year=1984&amp;journal=J+Clin+Oncol&amp;pages=187-193&amp;doi=10.1200%2FJCO.1984.2.3.187&amp;pmid=6699671" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. <em>J Clin Oncol</em> 2002;20:289-296.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2002.20.1.289" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11773181/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000173231900037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon-alfa+as+a+comparative+treatment+for+clinical+trials+of+new+therapies+against+advanced+renal+cell+carcinoma.&amp;publication_year=2002&amp;journal=J+Clin+Oncol&amp;pages=289-296&amp;doi=10.1200%2FJCO.2002.20.1.289&amp;pmid=11773181" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Molina AM, Hutson TE, Larkin J, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). <em>Cancer Chemother Pharmacol</em> 2014;73:181-189.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00280-013-2339-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24190702/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329223200021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+1b+clinical+trial+of+the+multi-targeted+tyrosine+kinase+inhibitor+lenvatinib+%28E7080%29+in+combination+with+everolimus+for+treatment+of+metastatic+renal+cell+carcinoma+%28RCC%29.&amp;publication_year=2014&amp;journal=Cancer+Chemother+Pharmacol&amp;pages=181-189&amp;doi=10.1007%2Fs00280-013-2339-y&amp;pmid=24190702" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content"><em>Lenvima (lenvatinib)</em>. Woodcliff Lake, NJ: Eisai, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvima+%28lenvatinib%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the results of phase 1 dose-finding trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] safety profiles for each combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. <em>Stat Biopharm Res</em> 2013;5:311-320.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19466315.2013.807748" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327394600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple+testing+in+group+sequential+trials+using+graphical+approaches.&amp;publication_year=2013&amp;journal=Stat+Biopharm+Res&amp;pages=311-320&amp;doi=10.1080%2F19466315.2013.807748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content"><em>Keytruda (pembrolizumab)</em>. Whitehouse Station, NJ: Merck Sharp &amp; Dohme, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Keytruda+%28pembrolizumab%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content"><em>Afinitor (everolimus)</em>. East Hanover, NJ: Novartis Pharmaceuticals, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Afinitor+%28everolimus%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. <em>J Clin Oncol</em> 2020;38:2981-2992.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.02627" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32167863/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000574584300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvatinib+plus+pembrolizumab+in+patients+with+advanced+endometrial+cancer.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=2981-2992&amp;doi=10.1200%2FJCO.19.02627&amp;pmid=32167863" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2020;21:1563-1573.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(20)30436-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33284113/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000599899200040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+axitinib+versus+sunitinib+monotherapy+as+first-line+treatment+of+advanced+renal+cell+carcinoma+%28KEYNOTE-426%29%3A+extended+follow-up+from+a+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet+Oncol&amp;pages=1563-1573&amp;doi=10.1016%2FS1470-2045%2820%2930436-8&amp;pmid=33284113" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/14"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">14</span></span> • <span property="datePublished">April 8, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1289</span>-<span property="pageEnd">1300</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2035716" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2035716?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: February 13, 2021</div><div><b class="core-label">Published in issue</b>: April 8, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/hematology-oncology-general" alt="View article keyword Hematology/Oncology General" data-interactiontype="article_recirculation_click">Hematology/Oncology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/nephrology-general" alt="View article keyword Nephrology General" data-interactiontype="article_recirculation_click">Nephrology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Motzer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Boris</span> <span property="familyName">Alekseev</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sun-Young</span> <span property="familyName">Rha</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Camillo</span> <span property="familyName">Porta</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Masatoshi</span> <span property="familyName">Eto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thomas</span> <span property="familyName">Powles</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Viktor</span> <span property="familyName">Grünwald</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thomas E.</span> <span property="familyName">Hutson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Evgeny</span> <span property="familyName">Kopyltsov</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">María J.</span> <span property="familyName">Méndez-Vidal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vadim</span> <span property="familyName">Kozlov</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anna</span> <span property="familyName">Alyasova</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sung-Hoo</span> <span property="familyName">Hong</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anil</span> <span property="familyName">Kapoor</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Teresa</span> <span property="familyName">Alonso Gordoa</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jaime R.</span> <span property="familyName">Merchan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eric</span> <span property="familyName">Winquist</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pablo</span> <span property="familyName">Maroto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jeffrey C.</span> <span property="familyName">Goh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Miso</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Howard</span> <span property="familyName">Gurney</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vijay</span> <span property="familyName">Patel</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Avivit</span> <span property="familyName">Peer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Giuseppe</span> <span property="familyName">Procopio</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Toshio</span> <span property="familyName">Takagi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bohuslav</span> <span property="familyName">Melichar</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Frederic</span> <span property="familyName">Rolland</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ugo</span> <span property="familyName">De Giorgi</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7520-2908" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7520-2908</a></span>, <span property="author" typeof="Person"><span property="givenName">Shirley</span> <span property="familyName">Wong</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jens</span> <span property="familyName">Bedke</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Manuela</span> <span property="familyName">Schmidinger</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Corina E.</span> <span property="familyName">Dutcus</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alan D.</span> <span property="familyName">Smith</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lea</span> <span property="familyName">Dutta</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kalgi</span> <span property="familyName">Mody</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rodolfo F.</span> <span property="familyName">Perini</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dongyuan</span> <span property="familyName">Xing</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Toni K.</span> <span property="familyName">Choueiri</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the CLEAR Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Memorial Sloan Kettering Cancer Center, New York (R.M.); P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.), the State Institution of Health Care Regional Clinical Oncology Dispensary, Omsk (E.K.), the State Budgetary Health Care Institution Novosibirsk Regional Clinical Oncology Dispensary, Novosibirsk (V.K.), and Prevoljskiy Region Medical Center, Novgorod (A.A.) — all in Russia; Yonsei Cancer Center, Yonsei University Health System (S.Y.R.), Seoul St. Mary’s Hospital, Catholic University of Korea (S.-H.H.), and Seoul National University Hospital (M.K.), Seoul, South Korea; San Matteo University Hospital Foundation, Pavia (C.P.), Istituto Nazionale dei Tumori IRCCS, Milan (G.P.), and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola (U.D.G.) — all in Italy; Kyushu University, Fukuoka (M.E.), and Tokyo Women’s Medical University, Tokyo (T.T.) — both in Japan; the Royal Free NHS Trust, London (T.P.), and Eisai, Hatfield (A.D.S.) — both in the United Kingdom; University Hospital Essen, Essen (V.G.), and the University of Tübingen, Tübingen (J.B.) — both in Germany; Texas Oncology, Dallas (T.E.H.); Maimonides Institute for Biomedical Research of Cordoba Hospital Universitario Reina Sofía, Medical Oncology Department, Córdoba (M.J.M.-V.), Hospital Universitario Ramón y Cajal, Madrid (T.A.G.), and Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.) — all in Spain; McMaster University, Hamilton (A.K.), and Western University, London (E.W.) — both in Ontario, Canada; the University of Miami Sylvester Comprehensive Cancer Center, Miami (J.R.M.), and Florida Cancer Specialists, Gainesville (V.P.); ICON Research, South Brisbane, and University of Queensland, St. Lucia, QLD (J.C.G.), Macquarie University, Sydney (H.G.), and Western Health, Melbourne, VIC (S.W.) — all in Australia; Rambam Health Care Campus, Haifa, Israel (A.P.); Palacky University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Centre René Gauducheau, Saint Herblain, France (F.R.); the Department of Urology, Medical University of Vienna, Vienna (M.S.); Eisai, Woodcliff Lake (C.E.D., L.D., K.M., D.X.), and Merck, Kenilworth (R.F.P.) — both in New Jersey; and Dana–Farber Cancer Institute, Boston (T.K.C.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Motzer at Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, or at <a href="mailto:motzerr@mskcc.org">motzerr@mskcc.org</a>; or to Dr. Choueiri at Dana–Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, or at <a href="mailto:toni_choueiri@dfci.harvard.edu">toni_choueiri@dfci.harvard.edu</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A full list of the CLEAR Trial Investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">1229</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2035716" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="47466611-ddfa-df55-b8e9-f3493f374b29"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005" style="display:inline-block;">
                <img alt="Article has an altmetric score of 445" src="https://badges.altmetric.com/?size=320&amp;score=445&amp;types=mabctwfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_47466611-ddfa-df55-b8e9-f3493f374b29" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=news">
          Picked up by <b>34</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=policy-documents">
          Referenced in <b>2</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=twitter">
          Posted by <b>284</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=100110005&amp;tab=guidelines">
          Referenced in <b>5</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>586</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d676f5c713f24b-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2035716"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2035716%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-14%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="1229" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michel Alchoueiry, </li><li class="list-inline-item cited-by__entry__author">Hadi Mansour, </li><li class="list-inline-item cited-by__entry__author">Damir Khabibullin, </li><li class="list-inline-item cited-by__entry__author">Tiegang Han, </li><li class="list-inline-item cited-by__entry__author">Saireudee Chaturantabut, </li><li class="list-inline-item cited-by__entry__author">Wafaa Bzeih, </li><li class="list-inline-item cited-by__entry__author">Yan Tang, </li><li class="list-inline-item cited-by__entry__author">Jessica F. Williams, </li><li class="list-inline-item cited-by__entry__author">Michelle S. Hirsch, </li><li class="list-inline-item cited-by__entry__author">Carmen Priolo, </li><li class="list-inline-item cited-by__entry__author">William R. Sellers, </li><li class="list-inline-item cited-by__entry__author">Elizabeth P. Henske, </li></ul><span class="cited-by__entry__title">Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma, </span><span class="cited-by__entry__series-title">Clinical Genitourinary Cancer, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(102359), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clgc.2025.102359" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clgc.2025.102359</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clgc.2025.102359" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shotaro Nakanishi, </li><li class="list-inline-item cited-by__entry__author">Junichi Inokuchi, </li></ul><span class="cited-by__entry__title">Current Evidences and Future Perspectives in the Management of Metastatic Non‐Clear Cell Renal Cell Carcinoma, </span><span class="cited-by__entry__series-title">International Journal of Urology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/iju.70144" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/iju.70144</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/iju.70144" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yuya Iwahashi, </li><li class="list-inline-item cited-by__entry__author">Yuko Ishida, </li><li class="list-inline-item cited-by__entry__author">Naofumi Mukaida, </li><li class="list-inline-item cited-by__entry__author">Toshikazu Kondo, </li></ul><span class="cited-by__entry__title">Pathophysiological Roles of the CX3CL1-CX3CR1 Axis in Renal Disease, Cardiovascular Disease, and Cancer, </span><span class="cited-by__entry__series-title">International Journal of Molecular Sciences, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(5352), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/ijms26115352" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/ijms26115352</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/ijms26115352" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Matteo Rosellini, </li><li class="list-inline-item cited-by__entry__author">Veronica Mollica, </li><li class="list-inline-item cited-by__entry__author">Andrea Marchetti, </li><li class="list-inline-item cited-by__entry__author">Sara Coluccelli, </li><li class="list-inline-item cited-by__entry__author">Francesca Giunchi, </li><li class="list-inline-item cited-by__entry__author">Elisa Tassinari, </li><li class="list-inline-item cited-by__entry__author">Linda Danielli, </li><li class="list-inline-item cited-by__entry__author">Thais Maloberti, </li><li class="list-inline-item cited-by__entry__author">Costantino Ricci, </li><li class="list-inline-item cited-by__entry__author">Michelangelo Fiorentino, </li><li class="list-inline-item cited-by__entry__author">Dario de Biase, </li><li class="list-inline-item cited-by__entry__author">Francesco Massari, </li></ul><span class="cited-by__entry__title">Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience, </span><span class="cited-by__entry__series-title">Pathology - Research and Practice, </span><span class="cited-by__entry__volume"><strong>270</strong>, </span><span class="cited-by__entry__page-range">(155964), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prp.2025.155964" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prp.2025.155964</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prp.2025.155964" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Victor Arias, </li><li class="list-inline-item cited-by__entry__author">Tatiana V. Kudling, </li><li class="list-inline-item cited-by__entry__author">James H.A. Clubb, </li><li class="list-inline-item cited-by__entry__author">Elise Jirovec, </li><li class="list-inline-item cited-by__entry__author">Santeri A. Pakola, </li><li class="list-inline-item cited-by__entry__author">Mirte Van der Heijden, </li><li class="list-inline-item cited-by__entry__author">Saru Basnet, </li><li class="list-inline-item cited-by__entry__author">Dafne C.A. Quixabeira, </li><li class="list-inline-item cited-by__entry__author">Lyna Haybout, </li><li class="list-inline-item cited-by__entry__author">Nea Ojala, </li><li class="list-inline-item cited-by__entry__author">Susanna Grönberg-Vähä-Koskela, </li><li class="list-inline-item cited-by__entry__author">Anna Kanerva, </li><li class="list-inline-item cited-by__entry__author">Antti Rannikko, </li><li class="list-inline-item cited-by__entry__author">João M. Santos, </li><li class="list-inline-item cited-by__entry__author">Victor Cervera-Carrascon, </li><li class="list-inline-item cited-by__entry__author">Otto Hemminki, </li><li class="list-inline-item cited-by__entry__author">Akseli Hemminki, </li></ul><span class="cited-by__entry__title">Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma, </span><span class="cited-by__entry__series-title">Molecular Therapy Oncology, </span><span class="cited-by__entry__volume"><strong>33</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(200979), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.omton.2025.200979" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.omton.2025.200979</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.omton.2025.200979" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">R. Stelmach, </li><li class="list-inline-item cited-by__entry__author">S. Erdmann, </li><li class="list-inline-item cited-by__entry__author">K. Schlack, </li><li class="list-inline-item cited-by__entry__author">C. Muehle, </li><li class="list-inline-item cited-by__entry__author">C. Darr, </li><li class="list-inline-item cited-by__entry__author">S. Neuberger, </li><li class="list-inline-item cited-by__entry__author">M. Reichert, </li><li class="list-inline-item cited-by__entry__author">L. Flegar, </li><li class="list-inline-item cited-by__entry__author">T. Egenolf, </li><li class="list-inline-item cited-by__entry__author">M. Rehlinghaus, </li><li class="list-inline-item cited-by__entry__author">F. Zengerling, </li><li class="list-inline-item cited-by__entry__author">J. Casuscelli, </li><li class="list-inline-item cited-by__entry__author">A. Cox, </li><li class="list-inline-item cited-by__entry__author">S. Vallet, </li><li class="list-inline-item cited-by__entry__author">T. Nestler, </li><li class="list-inline-item cited-by__entry__author">B. Brehmer, </li><li class="list-inline-item cited-by__entry__author">P. Ivanyi, </li><li class="list-inline-item cited-by__entry__author">P. Paffenholz, </li><li class="list-inline-item cited-by__entry__author">M. Neuberger, </li><li class="list-inline-item cited-by__entry__author">D. Jäger, </li><li class="list-inline-item cited-by__entry__author">V. Grünwald, </li><li class="list-inline-item cited-by__entry__author">S. Zschäbitz, </li></ul><span class="cited-by__entry__title">Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis, </span><span class="cited-by__entry__series-title">ESMO Real World Data and Digital Oncology, </span><span class="cited-by__entry__volume"><strong>8</strong>, </span><span class="cited-by__entry__page-range">(100142), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.esmorw.2025.100142" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.esmorw.2025.100142</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.esmorw.2025.100142" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Marco Stellato, </li><li class="list-inline-item cited-by__entry__author">Simone Rota, </li><li class="list-inline-item cited-by__entry__author">Melanie Claps, </li><li class="list-inline-item cited-by__entry__author">Valentina Guadalupi, </li><li class="list-inline-item cited-by__entry__author">Alessandro Rametta, </li><li class="list-inline-item cited-by__entry__author">Giuseppe Fotia, </li><li class="list-inline-item cited-by__entry__author">Marco Barella, </li><li class="list-inline-item cited-by__entry__author">Elena Verzoni, </li><li class="list-inline-item cited-by__entry__author">Giuseppe Procopio, </li></ul><span class="cited-by__entry__title">Pathological Complete Response in Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib Plus Nivolumab. Case Series and Literature Review, </span><span class="cited-by__entry__series-title">Clinical Genitourinary Cancer, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(102328), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clgc.2025.102328" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clgc.2025.102328</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clgc.2025.102328" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Masayuki Takahashi, </li><li class="list-inline-item cited-by__entry__author">Yuto Matsushita, </li><li class="list-inline-item cited-by__entry__author">Takahiro Kojima, </li><li class="list-inline-item cited-by__entry__author">Takahiro Osawa, </li><li class="list-inline-item cited-by__entry__author">Tomokazu Sazuka, </li><li class="list-inline-item cited-by__entry__author">Shingo Hatakeyama, </li><li class="list-inline-item cited-by__entry__author">Keisuke Goto, </li><li class="list-inline-item cited-by__entry__author">Kazuyuki Numakura, </li><li class="list-inline-item cited-by__entry__author">Kazutoshi Yamana, </li><li class="list-inline-item cited-by__entry__author">Shuya Kandori, </li><li class="list-inline-item cited-by__entry__author">Kazutoshi Fujita, </li><li class="list-inline-item cited-by__entry__author">Kosuke Ueda, </li><li class="list-inline-item cited-by__entry__author">Hajime Tanaka, </li><li class="list-inline-item cited-by__entry__author">Ryotaro Tomida, </li><li class="list-inline-item cited-by__entry__author">Toshifumi Kurahashi, </li><li class="list-inline-item cited-by__entry__author">Yukari Bando, </li><li class="list-inline-item cited-by__entry__author">Takahiro Kimura, </li><li class="list-inline-item cited-by__entry__author">Naotaka Nishiyama, </li><li class="list-inline-item cited-by__entry__author">Shimpei Yamashita, </li><li class="list-inline-item cited-by__entry__author">Hisanori Taniguchi, </li><li class="list-inline-item cited-by__entry__author">Keisuke Monji, </li><li class="list-inline-item cited-by__entry__author">Ryo Ishiyama, </li><li class="list-inline-item cited-by__entry__author">Yoshihide Kawasaki, </li><li class="list-inline-item cited-by__entry__author">Takuma Kato, </li><li class="list-inline-item cited-by__entry__author">Shuichi Tatarano, </li><li class="list-inline-item cited-by__entry__author">Kimihiko Masui, </li><li class="list-inline-item cited-by__entry__author">Eijiro Nakamura, </li><li class="list-inline-item cited-by__entry__author">Tomoyuki Kaneko, </li><li class="list-inline-item cited-by__entry__author">Makito Miyake, </li><li class="list-inline-item cited-by__entry__author">Goshi Kitano, </li><li class="list-inline-item cited-by__entry__author">Takanobu Motoshima, </li><li class="list-inline-item cited-by__entry__author">Yusuke Shiraishi, </li><li class="list-inline-item cited-by__entry__author">Satoru Kira, </li><li class="list-inline-item cited-by__entry__author">Takaya Murashima, </li><li class="list-inline-item cited-by__entry__author">Hiroaki Hara, </li><li class="list-inline-item cited-by__entry__author">Masafumi Matsumura, </li><li class="list-inline-item cited-by__entry__author">Hiroshi Kitamura, </li><li class="list-inline-item cited-by__entry__author">Hideaki Miyake, </li><li class="list-inline-item cited-by__entry__author">Junya Furukawa, </li></ul><span class="cited-by__entry__title">Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell Carcinoma, </span><span class="cited-by__entry__series-title">Clinical Genitourinary Cancer, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(102322), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clgc.2025.102322" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clgc.2025.102322</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clgc.2025.102322" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Bradley A. McGregor, </li><li class="list-inline-item cited-by__entry__author">Wanling Xie, </li><li class="list-inline-item cited-by__entry__author">Stephanie A. Berg, </li><li class="list-inline-item cited-by__entry__author">Wenxin Xu, </li><li class="list-inline-item cited-by__entry__author">Srinivas R. Viswanathan, </li><li class="list-inline-item cited-by__entry__author">David McDermott, </li><li class="list-inline-item cited-by__entry__author">Sabina Signoretti, </li><li class="list-inline-item cited-by__entry__author">William G Kaelin, </li><li class="list-inline-item cited-by__entry__author">Toni K. Choueiri, </li></ul><span class="cited-by__entry__title">CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma, </span><span class="cited-by__entry__series-title">Clinical Genitourinary Cancer, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(102318), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clgc.2025.102318" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clgc.2025.102318</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clgc.2025.102318" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kohei Shitara, </li><li class="list-inline-item cited-by__entry__author">Sylvie Lorenzen, </li><li class="list-inline-item cited-by__entry__author">Jin Li, </li><li class="list-inline-item cited-by__entry__author">Yuxian Bai, </li><li class="list-inline-item cited-by__entry__author">Manuel González Fernández, </li><li class="list-inline-item cited-by__entry__author">Mynor Aguilar, </li><li class="list-inline-item cited-by__entry__author">Hirokazu Shoji, </li><li class="list-inline-item cited-by__entry__author">Felipe Reyes-Cosmelli, </li><li class="list-inline-item cited-by__entry__author">Yovany Rodriguez Peña, </li><li class="list-inline-item cited-by__entry__author">Luis Corrales, </li><li class="list-inline-item cited-by__entry__author">Lucjan Wyrwicz, </li><li class="list-inline-item cited-by__entry__author">Daniel Acosta Eyzaguirre, </li><li class="list-inline-item cited-by__entry__author">Yueyin Pan, </li><li class="list-inline-item cited-by__entry__author">Min-Hee Ryu, </li><li class="list-inline-item cited-by__entry__author">Deirdre J. Cohen, </li><li class="list-inline-item cited-by__entry__author">Zev A. Wainberg, </li><li class="list-inline-item cited-by__entry__author">Geoffrey Ku, </li><li class="list-inline-item cited-by__entry__author">Josep Tabernero, </li><li class="list-inline-item cited-by__entry__author">Eric Van Cutsem, </li><li class="list-inline-item cited-by__entry__author">Shu-Kui Qin, </li><li class="list-inline-item cited-by__entry__author">Do-Youn Oh, </li><li class="list-inline-item cited-by__entry__author">Jianming Xu, </li><li class="list-inline-item cited-by__entry__author">Li Wen Liang, </li><li class="list-inline-item cited-by__entry__author">Sonal Bordia, </li><li class="list-inline-item cited-by__entry__author">Pooja Bhagia, </li><li class="list-inline-item cited-by__entry__author">Sun Young Rha, </li><li class="list-inline-item cited-by__entry__author">Ezequiel Heman Slutsky, </li><li class="list-inline-item cited-by__entry__author">Juan Cundom, </li><li class="list-inline-item cited-by__entry__author">Andrea Gabriela Soria, </li><li class="list-inline-item cited-by__entry__author">Marcela Alejandro Carballido, </li><li class="list-inline-item cited-by__entry__author">Juan Manuel O'Connor, </li><li class="list-inline-item cited-by__entry__author">Julieta Grasseli, </li><li class="list-inline-item cited-by__entry__author">Matthew Burge, </li><li class="list-inline-item cited-by__entry__author">Daniel Paul Brungs, </li><li class="list-inline-item cited-by__entry__author">Muhammad Adnan Khattak, </li><li class="list-inline-item cited-by__entry__author">Karen Paula Jozefa Geboes, </li><li class="list-inline-item cited-by__entry__author">Eric Van Cutsem, </li><li class="list-inline-item cited-by__entry__author">Jeroen Dekervel, </li><li class="list-inline-item cited-by__entry__author">Lionel D. Hondt, </li><li class="list-inline-item cited-by__entry__author">Frederic Lemay, </li><li class="list-inline-item cited-by__entry__author">Rosalyn Anne Juergens, </li><li class="list-inline-item cited-by__entry__author">Felipe Reyes, </li><li class="list-inline-item cited-by__entry__author">Gonzalo Pizarro Brito, </li><li class="list-inline-item cited-by__entry__author">Maria Alejandra Ojeda, </li><li class="list-inline-item cited-by__entry__author">Herman Adolfo Araya, </li><li class="list-inline-item cited-by__entry__author">Patricio Eduardo Yanez, </li><li class="list-inline-item cited-by__entry__author">Jianwei Yang, </li><li class="list-inline-item cited-by__entry__author">Xi Chen, </li><li class="list-inline-item cited-by__entry__author">Yuxian Bai, </li><li class="list-inline-item cited-by__entry__author">Hongming Pan, </li><li class="list-inline-item cited-by__entry__author">Nong Xu, </li><li class="list-inline-item cited-by__entry__author">Yueyin Pan, </li><li class="list-inline-item cited-by__entry__author">Qinghong Guo, </li><li class="list-inline-item cited-by__entry__author">Baorui Liu, </li><li class="list-inline-item cited-by__entry__author">Feng Ye, </li><li class="list-inline-item cited-by__entry__author">Xin Wang, </li><li class="list-inline-item cited-by__entry__author">Qi Li, </li><li class="list-inline-item cited-by__entry__author">Yong Tang, </li><li class="list-inline-item cited-by__entry__author">Huiting Xu, </li><li class="list-inline-item cited-by__entry__author">Haichuan Su, </li><li class="list-inline-item cited-by__entry__author">Ying Cheng, </li><li class="list-inline-item cited-by__entry__author">Xianli Yin, </li><li class="list-inline-item cited-by__entry__author">Qun Zhao, </li><li class="list-inline-item cited-by__entry__author">Ning Li, </li><li class="list-inline-item cited-by__entry__author">Jun You, </li><li class="list-inline-item cited-by__entry__author">Yi Ba, </li><li class="list-inline-item cited-by__entry__author">Jinsheng We, </li><li class="list-inline-item cited-by__entry__author">Lin Shen, </li><li class="list-inline-item cited-by__entry__author">Jin Li, </li><li class="list-inline-item cited-by__entry__author">Wangjun Liao, </li><li class="list-inline-item cited-by__entry__author">Zhen Li, </li><li class="list-inline-item cited-by__entry__author">Lei Yang, </li><li class="list-inline-item cited-by__entry__author">Yovany Eduardo Rodriguez Pena, </li><li class="list-inline-item cited-by__entry__author">Ivan Jose Bustillo, </li><li class="list-inline-item cited-by__entry__author">Carlos Jose Narvaez, </li><li class="list-inline-item cited-by__entry__author">Manuel Enrique Gonzalez Fernandez, </li><li class="list-inline-item cited-by__entry__author">Raimundo Manneh, </li><li class="list-inline-item cited-by__entry__author">Andres Fernando Arenas Arias, </li><li class="list-inline-item cited-by__entry__author">Luis Corrales, </li><li class="list-inline-item cited-by__entry__author">Andres Wiernik Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Thomas Aparicio, </li><li class="list-inline-item cited-by__entry__author">Yuan Touchefeu, </li><li class="list-inline-item cited-by__entry__author">Helene Boussion-Desloges, </li><li class="list-inline-item cited-by__entry__author">Laurent Mineur, </li><li class="list-inline-item cited-by__entry__author">Christophe Tournigand, </li><li class="list-inline-item cited-by__entry__author">Francois Ghiringhelli, </li><li class="list-inline-item cited-by__entry__author">Marie Pierre Galais, </li><li class="list-inline-item cited-by__entry__author">Eric Terrebonne, </li><li class="list-inline-item cited-by__entry__author">Thomas Walter, </li><li class="list-inline-item cited-by__entry__author">Mathieu Baconnier, </li><li class="list-inline-item cited-by__entry__author">Sylvie Lorenzen, </li><li class="list-inline-item cited-by__entry__author">Eray Goekkurt, </li><li class="list-inline-item cited-by__entry__author">Annika Kurreck, </li><li class="list-inline-item cited-by__entry__author">Arne Kandulski, </li><li class="list-inline-item cited-by__entry__author">Thorsten Goetze, </li><li class="list-inline-item cited-by__entry__author">Florian Lordick, </li><li class="list-inline-item cited-by__entry__author">Mynor Aguilar, </li><li class="list-inline-item cited-by__entry__author">Karla Alejandra Lopez, </li><li class="list-inline-item cited-by__entry__author">Rixci Augusto Lenin Ramirez Fallas, </li><li class="list-inline-item cited-by__entry__author">Pier Anyelo Ramos Elias, </li><li class="list-inline-item cited-by__entry__author">Juan Pablo Moreira, </li><li class="list-inline-item cited-by__entry__author">Wing Lok Wendy Chan, </li><li class="list-inline-item cited-by__entry__author">Ashely Cheng, </li><li class="list-inline-item cited-by__entry__author">Winnie Yeo, </li><li class="list-inline-item cited-by__entry__author">Maeve Lowery, </li><li class="list-inline-item cited-by__entry__author">Adrian Murphy, </li><li class="list-inline-item cited-by__entry__author">Sharon Pelles Avraham, </li><li class="list-inline-item cited-by__entry__author">Ayala Hubert, </li><li class="list-inline-item cited-by__entry__author">Irit Ben-Aharon, </li><li class="list-inline-item cited-by__entry__author">Valeriya Semenisty, </li><li class="list-inline-item cited-by__entry__author">Gali Perl, </li><li class="list-inline-item cited-by__entry__author">Wael Hozaeel, </li><li class="list-inline-item cited-by__entry__author">Armando Santoro, </li><li class="list-inline-item cited-by__entry__author">Elena Aurelia Mazza, </li><li class="list-inline-item cited-by__entry__author">Ferdinando de Vita, </li><li class="list-inline-item cited-by__entry__author">Guiseppe Aprile, </li><li class="list-inline-item cited-by__entry__author">Giovanni Gerardo Cardellino, </li><li class="list-inline-item cited-by__entry__author">Filippo Pietrantonio, </li><li class="list-inline-item cited-by__entry__author">Pierfrancesco Tassone, </li><li class="list-inline-item cited-by__entry__author">Kohei Shitara, </li><li class="list-inline-item cited-by__entry__author">Hirokazu Shoji, </li><li class="list-inline-item cited-by__entry__author">Yukiya Narita, </li><li class="list-inline-item cited-by__entry__author">Hiroki Hara, </li><li class="list-inline-item cited-by__entry__author">Kensei Yamaguchi, </li><li class="list-inline-item cited-by__entry__author">Naotoshi Sugimoto, </li><li class="list-inline-item cited-by__entry__author">Nozomu Machida, </li><li class="list-inline-item cited-by__entry__author">Tomohiro Nishina, </li><li class="list-inline-item cited-by__entry__author">Akihito Tsuji, </li><li class="list-inline-item cited-by__entry__author">Yasuhiro Choda, </li><li class="list-inline-item cited-by__entry__author">Kenji Amagai, </li><li class="list-inline-item cited-by__entry__author">Masahiro Tsuda, </li><li class="list-inline-item cited-by__entry__author">Shogen Boku, </li><li class="list-inline-item cited-by__entry__author">Boguslawa Karaszewska, </li><li class="list-inline-item cited-by__entry__author">Kamil Stanislaw Kuc, </li><li class="list-inline-item cited-by__entry__author">Jacek Mackiewicz, </li><li class="list-inline-item cited-by__entry__author">Lucjan Stanislaw Wyrwicz, </li><li class="list-inline-item cited-by__entry__author">Lukasz Hajac, </li><li class="list-inline-item cited-by__entry__author">Alexy Alexandrovich Tryakin, </li><li class="list-inline-item cited-by__entry__author">Dmitry Aleksandrovich Nosov, </li><li class="list-inline-item cited-by__entry__author">Rashida Orlova, </li><li class="list-inline-item cited-by__entry__author">Alexey Mikhailovich Karachun, </li><li class="list-inline-item cited-by__entry__author">Michael Osipov, </li><li class="list-inline-item cited-by__entry__author">Mikhail Valerievich Kopp, </li><li class="list-inline-item cited-by__entry__author">Natalia Vladimirovna Fadeeva, </li><li class="list-inline-item cited-by__entry__author">Nikolay Viktorovich Kislov, </li><li class="list-inline-item cited-by__entry__author">Sun Young Rha, </li><li class="list-inline-item cited-by__entry__author">Seung Tae Kim, </li><li class="list-inline-item cited-by__entry__author">Min-Hee Ryu, </li><li class="list-inline-item cited-by__entry__author">Do-Youn Oh, </li><li class="list-inline-item cited-by__entry__author">Keun-Wook Lee, </li><li class="list-inline-item cited-by__entry__author">Hei-Cheul Jeung, </li><li class="list-inline-item cited-by__entry__author">Jonggwon Choi, </li><li class="list-inline-item cited-by__entry__author">Sang Cheul Oh, </li><li class="list-inline-item cited-by__entry__author">Paula Jimenez Fonseca, </li><li class="list-inline-item cited-by__entry__author">Fernando Rivera Herrero, </li><li class="list-inline-item cited-by__entry__author">Pilar Aitana Calvo Ferrandiz, </li><li class="list-inline-item cited-by__entry__author">Daniel Acosta Eyzaguirre, </li><li class="list-inline-item cited-by__entry__author">Kun-Huei Yeh, </li><li class="list-inline-item cited-by__entry__author">Jen-Shi Chen, </li><li class="list-inline-item cited-by__entry__author">Li-Yuan Bai, </li><li class="list-inline-item cited-by__entry__author">Chia-Jui Yen, </li><li class="list-inline-item cited-by__entry__author">Bulent Erdogan, </li><li class="list-inline-item cited-by__entry__author">Pinar Gursoy, </li><li class="list-inline-item cited-by__entry__author">Mustafa Ozguroglu, </li><li class="list-inline-item cited-by__entry__author">Suayib Yalcin, </li><li class="list-inline-item cited-by__entry__author">Umut Demirci, </li><li class="list-inline-item cited-by__entry__author">Mehmet Bilici, </li><li class="list-inline-item cited-by__entry__author">Ilhan Hacibekiroglu, </li><li class="list-inline-item cited-by__entry__author">Hugo Ford, </li><li class="list-inline-item cited-by__entry__author">Kai-Keen Shiu, </li><li class="list-inline-item cited-by__entry__author">Martin Scott-Brown, </li><li class="list-inline-item cited-by__entry__author">Russell Petty, </li><li class="list-inline-item cited-by__entry__author">Wasat Mansoor, </li><li class="list-inline-item cited-by__entry__author">Zev A. Wainberg, </li><li class="list-inline-item cited-by__entry__author">Marcus Noel, </li><li class="list-inline-item cited-by__entry__author">Peter Enzinger, </li><li class="list-inline-item cited-by__entry__author">Sreenivasa Chandana, </li><li class="list-inline-item cited-by__entry__author">Geoffrey Ku, </li><li class="list-inline-item cited-by__entry__author">Dierdre Cohen, </li><li class="list-inline-item cited-by__entry__author">Vincent Lam, </li></ul><span class="cited-by__entry__title">Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study, </span><span class="cited-by__entry__series-title">Journal of Clinical Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/JCO-25-00748" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/JCO-25-00748</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/JCO-25-00748" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2035716%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-14%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2035716" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035716.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f1.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/67b0cb54-4861-4465-8bb4-e241e025fc50/assets/images/large/nejmoa2035716_f1.jpg" height="3065" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Panel A shows the Kaplan–Meier curves for progression-free survival in each treatment group. Tick marks indicate censored data. Panel B shows the analysis of progression-free survival in subgroups of patients in the lenvatinib-plus-pembrolizumab group and the sunitinib group. Progression-free survival was assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent review committee. Differences between the treatment groups were evaluated with the stratified log-rank test, stratified according to geographic region and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk group. A stratified Cox regression model was used to estimate the hazard ratio for disease progression or death and 95% confidence intervals (CIs). MSKCC and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups are defined in the <a href="#ap2">Supplementary Appendix</a>. Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability. The programmed cell death ligand 1 (PD-L1) combined positive score is defined as the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f2.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/99e0f0f6-c8fb-4199-8345-a60705f5486a/assets/images/large/nejmoa2035716_f2.jpg" height="2280" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival and Duration of Response.</div><div class="notes"><div role="doc-footnote">Panel A shows the Kaplan–Meier curves for overall survival, and Panel B shows the Kaplan–Meier curves for the duration of response in patients who had a response. Tick marks indicate censored data. NE denotes could not be estimated, and NR not reached.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035716/asset/d8f9b074-98dd-4e1d-8ec6-17d2f1ad4acb/assets/images/large/nejmoa2035716_t1.jpg" height="2817" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Lenvatinib plus Pembrolizumab<br>(N=355)</th><th class="txxx-borders">Lenvatinib plus Everolimus<br>(N=357)</th><th class="txxr-borders">Sunitinib<br>(N=357)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">64 (34–88)</td><td class="xxxx-borders shading">62 (32–86)</td><td class="xxxr-borders shading">61 (29–82)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age &lt;65 yr — no. (%)</td><td class="xxxx-borders">194 (54.6)</td><td class="xxxx-borders">201 (56.3)</td><td class="xxxr-borders">225 (63.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Male</td><td class="xxxx-borders">255 (71.8)</td><td class="xxxx-borders">266 (74.5)</td><td class="xxxr-borders">275 (77.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">100 (28.2)</td><td class="xxxx-borders shading">91 (25.5)</td><td class="xxxr-borders shading">82 (23.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Geographic region — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Western Europe or North America</td><td class="xxxx-borders shading">198 (55.8)</td><td class="xxxx-borders shading">200 (56.0)</td><td class="xxxr-borders shading">199 (55.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rest of the world</td><td class="xxxx-borders">157 (44.2)</td><td class="xxxx-borders">157 (44.0)</td><td class="xxxr-borders">158 (44.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Karnofsky performance-status score — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">100–90</td><td class="xxxx-borders">295 (83.1)</td><td class="xxxx-borders">286 (80.1)</td><td class="xxxr-borders">294 (82.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">80–70</td><td class="xxxx-borders shading">60 (16.9)</td><td class="xxxx-borders shading">70 (19.6)</td><td class="xxxr-borders shading">62 (17.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">MSKCC prognostic risk group — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Favorable</td><td class="xxxx-borders shading">96 (27.0)</td><td class="xxxx-borders shading">98 (27.5)</td><td class="xxxr-borders shading">97 (27.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">227 (63.9)</td><td class="xxxx-borders">227 (63.6)</td><td class="xxxr-borders">228 (63.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor</td><td class="xxxx-borders shading">32 (9.0)</td><td class="xxxx-borders shading">32 (9.0)</td><td class="xxxr-borders shading">32 (9.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IMDC prognostic risk group — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Favorable</td><td class="xxxx-borders shading">110 (31.0)</td><td class="xxxx-borders shading">114 (31.9)</td><td class="xxxr-borders shading">124 (34.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">210 (59.2)</td><td class="xxxx-borders">195 (54.6)</td><td class="xxxr-borders">192 (53.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor</td><td class="xxxx-borders shading">33 (9.3)</td><td class="xxxx-borders shading">42 (11.8)</td><td class="xxxr-borders shading">37 (10.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Could not be evaluated</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxr-borders">4 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Sarcomatoid features — no. (%)</td><td class="xxxx-borders shading">28 (7.9)</td><td class="xxxx-borders shading">24 (6.7)</td><td class="xxxr-borders shading">21 (5.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">PD-L1 combined positive score — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥1</td><td class="xxxx-borders shading">107 (30.1)</td><td class="xxxx-borders shading">116 (32.5)</td><td class="xxxr-borders shading">119 (33.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1</td><td class="xxxx-borders">112 (31.5)</td><td class="xxxx-borders">118 (33.1)</td><td class="xxxr-borders">103 (28.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Not available</td><td class="xxxx-borders shading">136 (38.3)</td><td class="xxxx-borders shading">123 (34.5)</td><td class="xxxr-borders shading">135 (37.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of metastatic organs or sites — no. (%)<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">97 (27.3)</td><td class="xxxx-borders shading">125 (35.0)</td><td class="xxxr-borders shading">108 (30.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥2</td><td class="xxxx-borders">254 (71.5)</td><td class="xxxx-borders">229 (64.1)</td><td class="xxxr-borders">246 (68.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Site of metastasis — no. (%)<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lung</td><td class="xxxx-borders">249 (70.1)</td><td class="xxxx-borders">245 (68.6)</td><td class="xxxr-borders">239 (66.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lymph node</td><td class="xxxx-borders shading">170 (47.9)</td><td class="xxxx-borders shading">163 (45.7)</td><td class="xxxr-borders shading">159 (44.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bone</td><td class="xxxx-borders">85 (23.9)</td><td class="xxxx-borders">86 (24.1)</td><td class="xxxr-borders">97 (27.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Liver</td><td class="xxxx-borders shading">60 (16.9)</td><td class="xxxx-borders shading">62 (17.4)</td><td class="xxxr-borders shading">61 (17.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Previous nephrectomy — no. (%)</td><td class="xbxx-borders">262 (73.8)</td><td class="xbxx-borders">260 (72.8)</td><td class="xbxr-borders">275 (77.0)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Percentages may not total 100 because of rounding. One patient in the lenvatinib-plus-pembrolizumab group had carcinoma without a clear-cell component.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability. Scores were missing for 1 patient each in the lenvatinib-plus-everolimus and sunitinib groups.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg"><div class="label">‡</div></a><div id="core-t1fn3" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg">A Memorial Sloan Kettering Cancer Center (MSKCC) score of 0 indicates favorable risk, a score of 1 or 2 intermediate risk, and a score of 3 or higher poor risk. MSKCC scores are defined in the </a><a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score of 0 indicates favorable risk, a score of 1 or 2 intermediate risk, and a score of 3 to 6 poor risk. IMDC scores are defined in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Programmed cell death ligand 1 (PD-L1) expression was assessed with the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) and reported as the combined positive score, defined as the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Kidney was not included in the number of metastatic organs or sites. The only tumor location was in the kidney for 3 patients (0.8%) in the lenvatinib-plus-everolimus group, 4 patients (1.1%) in the lenvatinib-plus-pembrolizumab group, and 3 patients (0.8%) in the sunitinib group.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Four common sites of metastasis are shown. Patients may have had metastasis at more than one site.</div></div></div></figcaption><figcaption><div class="caption">Demographic and Clinical Characteristics at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035716/asset/fdf0f359-b94c-49c1-806d-4a73d64db39c/assets/images/large/nejmoa2035716_t2.jpg" height="1171" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Measure</th><th class="txxx-borders">Lenvatinib plus Pembrolizumab<br>(N=355)</th><th class="txxx-borders">Lenvatinib plus Everolimus<br>(N=357)</th><th class="txxr-borders">Sunitinib<br>(N=357)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Objective response (95% CI) — %<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">71.0 (66.3–75.7)</td><td class="xxxx-borders shading">53.5 (48.3–58.7)</td><td class="xxxr-borders shading">36.1 (31.2–41.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relative risk vs. sunitinib (95% CI)</td><td class="xxxx-borders">1.97 (1.69–2.29)</td><td class="xxxx-borders">1.48 (1.26–1.74)</td><td class="xxxr-borders">Reference</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Best overall response — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response</td><td class="xxxx-borders">57 (16.1)</td><td class="xxxx-borders">35 (9.8)</td><td class="xxxr-borders">15 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response</td><td class="xxxx-borders shading">195 (54.9)</td><td class="xxxx-borders shading">156 (43.7)</td><td class="xxxr-borders shading">114 (31.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable disease</td><td class="xxxx-borders">68 (19.2)</td><td class="xxxx-borders">120 (33.6)</td><td class="xxxr-borders">136 (38.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive disease</td><td class="xxxx-borders shading">19 (5.4)</td><td class="xxxx-borders shading">26 (7.3)</td><td class="xxxr-borders shading">50 (14.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unknown or could not be evaluated<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">16 (4.5)</td><td class="xxxx-borders">20 (5.6)</td><td class="xxxr-borders">42 (11.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to response (range) — mo</td><td class="xxxx-borders shading">1.94 (1.41–18.50)</td><td class="xxxx-borders shading">1.91 (1.41–14.36)</td><td class="xxxr-borders shading">1.94 (1.61–16.62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xbxx-borders">25.8 (22.1–27.9)</td><td class="xbxx-borders">16.6 (14.6–20.6)</td><td class="xbxr-borders">14.6 (9.4–16.7)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Responses were assessed by an independent review committee with Response Evaluation Criteria in Solid Tumors, version 1.1. Percentages may not total 100 due to rounding.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg"><div class="label">†</div></a><div id="core-t2fn2" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg">Additional details of the statistical analysis and the results of interim analysis 2 (a prespecified interim analysis that had been planned as the final analysis of objective response) are provided in the </a><a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The best overall response was unknown or could not be evaluated for patients who had no baseline or no postbaseline tumor assessments, at least one lesion that could not be evaluated, or early stable disease (occurring &lt;7 weeks after randomization).</div></div></div></figcaption><figcaption><div class="caption">Confirmed Tumor Responses.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035716/asset/e358eb5a-f753-4c39-b6c2-2496415d077e/assets/images/large/nejmoa2035716_t3.jpg" height="2029" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Lenvatinib plus Pembrolizumab<br>(N=352)</span></th><th class="txxx-borders" colspan="2"><span>Lenvatinib plus Everolimus<br>(N=355)</span></th><th class="txxr-borders" colspan="2"><span>Sunitinib<br>(N=340)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade ≥3<a href="#core-t3fn2" role="doc-noteref">†</a></th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade ≥3<a href="#core-t3fn2" role="doc-noteref">†</a></th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade ≥3<a href="#core-t3fn2" role="doc-noteref">†</a></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any event</td><td class="xxxx-borders shading">351 (99.7)</td><td class="xxxx-borders shading">290 (82.4)</td><td class="xxxx-borders shading">354 (99.7)</td><td class="xxxx-borders shading">295 (83.1)</td><td class="xxxx-borders shading">335 (98.5)</td><td class="xxxr-borders shading">244 (71.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">216 (61.4)</td><td class="xxxx-borders">34 (9.7)</td><td class="xxxx-borders">236 (66.5)</td><td class="xxxx-borders">41 (11.5)</td><td class="xxxx-borders">168 (49.4)</td><td class="xxxr-borders">18 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">195 (55.4)</td><td class="xxxx-borders shading">97 (27.6)</td><td class="xxxx-borders shading">162 (45.6)</td><td class="xxxx-borders shading">80 (22.5)</td><td class="xxxx-borders shading">141 (41.5)</td><td class="xxxr-borders shading">64 (18.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hypothyroidism<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">166 (47.2)</td><td class="xxxx-borders">5 (1.4)</td><td class="xxxx-borders">95 (26.8)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">90 (26.5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">142 (40.3)</td><td class="xxxx-borders shading">14 (4.0)</td><td class="xxxx-borders shading">144 (40.6)</td><td class="xxxx-borders shading">22 (6.2)</td><td class="xxxx-borders shading">105 (30.9)</td><td class="xxxr-borders shading">5 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">141 (40.1)</td><td class="xxxx-borders">15 (4.3)</td><td class="xxxx-borders">149 (42.0)</td><td class="xxxx-borders">27 (7.6)</td><td class="xxxx-borders">125 (36.8)</td><td class="xxxr-borders">15 (4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">126 (35.8)</td><td class="xxxx-borders shading">9 (2.6)</td><td class="xxxx-borders shading">141 (39.7)</td><td class="xxxx-borders shading">9 (2.5)</td><td class="xxxx-borders shading">113 (33.2)</td><td class="xxxr-borders shading">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Stomatitis</td><td class="xxxx-borders">122 (34.7)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxx-borders">169 (47.6)</td><td class="xxxx-borders">22 (6.2)</td><td class="xxxx-borders">131 (38.5)</td><td class="xxxr-borders">7 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Dysphonia</td><td class="xxxx-borders shading">105 (29.8)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">84 (23.7)</td><td class="xxxx-borders shading">2 (0.6)</td><td class="xxxx-borders shading">14 (4.1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Weight decrease</td><td class="xxxx-borders">105 (29.8)</td><td class="xxxx-borders">28 (8.0)</td><td class="xxxx-borders">116 (32.7)</td><td class="xxxx-borders">26 (7.3)</td><td class="xxxx-borders">31 (9.1)</td><td class="xxxr-borders">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Proteinuria</td><td class="xxxx-borders shading">104 (29.5)</td><td class="xxxx-borders shading">27 (7.7)</td><td class="xxxx-borders shading">121 (34.1)</td><td class="xxxx-borders shading">29 (8.2)</td><td class="xxxx-borders shading">43 (12.6)</td><td class="xxxr-borders shading">10 (2.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Palmar–plantar erythrodysesthesia syndrome</td><td class="xxxx-borders">101 (28.7)</td><td class="xxxx-borders">14 (4.0)</td><td class="xxxx-borders">81 (22.8)</td><td class="xxxx-borders">10 (2.8)</td><td class="xxxx-borders">127 (37.4)</td><td class="xxxr-borders">13 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Arthralgia</td><td class="xxxx-borders shading">99 (28.1)</td><td class="xxxx-borders shading">5 (1.4)</td><td class="xxxx-borders shading">76 (21.4)</td><td class="xxxx-borders shading">5 (1.4)</td><td class="xxxx-borders shading">52 (15.3)</td><td class="xxxr-borders shading">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rash</td><td class="xxxx-borders">96 (27.3)</td><td class="xxxx-borders">13 (3.7)</td><td class="xxxx-borders">88 (24.8)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">47 (13.8)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">92 (26.1)</td><td class="xxxx-borders shading">12 (3.4)</td><td class="xxxx-borders shading">113 (31.8)</td><td class="xxxx-borders shading">10 (2.8)</td><td class="xxxx-borders shading">68 (20.0)</td><td class="xxxr-borders shading">5 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">89 (25.3)</td><td class="xxxx-borders">3 (0.9)</td><td class="xxxx-borders">73 (20.6)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">64 (18.8)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Dysgeusia</td><td class="xbxx-borders shading">43 (12.2)</td><td class="xbxx-borders shading">1 (0.3)</td><td class="xbxx-borders shading">59 (16.6)</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">95 (27.9)</td><td class="xbxr-borders shading">1 (0.3)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Safety assessments were based on as-treated principle and consisted of monitoring and recording all adverse events and serious adverse events with the use of the Common Terminology Criteria for Adverse Events, version 4.03, in the group of patients who received at least one dose of trial drug. Events are listed in descending order of frequency in the lenvatinib-plus-pembrolizumab group. Adverse events were coded to the <i>Medical Dictionary for Regulatory Activities</i>, version 21.1 or higher, lower-level term closest to the verbatim term.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Of the 15 patients in the lenvatinib-plus-pembrolizumab group who had grade 5 adverse events during treatment, 11 had fatal events not attributed to disease progression (acute renal failure, uncontrolled hypertension, complications from myasthenic syndrome, complications from autoimmune hepatitis, cardiac arrest, and death–cause not specified in 1 patient each; hemorrhagic events in 2 patients; and sepsis in 3 patients). In the lenvatinib-plus-everolimus group, of the 22 patients with grade 5 adverse events, 10 had fatal events not attributed to disease progression (pneumonia, urosepsis, colon perforation, fistula, infection, and pneumothorax in 1 patient each; hemorrhagic events and death–cause not specified in 2 patients each). Among the 11 patients in the sunitinib group with grade 5 adverse events during treatment, fatal events not attributed to disease progression occurred in 2 patients (respiratory failure and acute kidney injury in 1 patient and death–cause not specified in 1 patient).</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg"><div class="label">‡</div></a><div id="core-t3fn3" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg">Hypothyroidism is an adverse event of interest associated with pembrolizumab; additional information regarding adverse events of interest is provided in the </a><a href="#ap2">Supplementary Appendix</a>. Information regarding these adverse events was not collected specifically as “immune-related,” in order to preserve blinding.</div></div></div></figcaption><figcaption><div class="caption">Adverse Events of Any Cause That Emerged or Worsened during Treatment in at Least 25% of the Patients in Any Treatment Group.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035716_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2035716</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. <em>N Engl J Med</em> 2017;376:354-366.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMra1601333&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28121507/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393111600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+therapy+for+metastatic+renal-cell+carcinoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=354-366&amp;doi=10.1056%2FNEJMra1601333&amp;pmid=28121507" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. <em>Nat Med</em> 2020;26:1519-1530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-020-1093-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33020645/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000575801100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+the+HIF2-VEGF+axis+in+renal+cell+carcinoma.&amp;publication_year=2020&amp;journal=Nat+Med&amp;pages=1519-1530&amp;doi=10.1038%2Fs41591-020-1093-z&amp;pmid=33020645" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Choueiri TK, Powles T, Burotto M, et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. <em>Ann Oncol</em> 2020;31:Suppl 4:S1159-S1159. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2020.08.2257" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000573469102655" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+%2B+cabozantinib+vs+sunitinib+in+first-line+treatment+for+advanced+renal+cell+carcinoma%3A+first+results+from+the+randomized+phase+III+CheckMate+9ER+trial&amp;publication_year=2020&amp;journal=Ann+Oncol&amp;pages=S1159-S1159&amp;doi=10.1016%2Fj.annonc.2020.08.2257" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. <em>N Engl J Med</em> 2018;378:1277-1290.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMoa1712126&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29562145/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429105700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+versus+sunitinib+in+advanced+renal-cell+carcinoma.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=1277-1290&amp;doi=10.1056%2FNEJMoa1712126&amp;pmid=29562145" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <em>N Engl J Med</em> 2019;380:1103-1115.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMoa1816047&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30779531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461898400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab+plus+axitinib+versus+sunitinib+for+advanced+renal-cell+carcinoma.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1103-1115&amp;doi=10.1056%2FNEJMoa1816047&amp;pmid=30779531" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <em>N Engl J Med</em> 2019;380:1116-1127.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035716&amp;key=10.1056%2FNEJMoa1816714&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30779529/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461898400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+axitinib+versus+sunitinib+for+advanced+renal-cell+carcinoma.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1116-1127&amp;doi=10.1056%2FNEJMoa1816714&amp;pmid=30779529" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with metastatic renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. <em>Ther Adv Med Oncol</em> 2020;12:1758835920907504-1758835920907504.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1758835920907504" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32215057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000524681900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tyrosine+kinase+inhibitors+and+immunotherapy+combinations+in+renal+cell+carcinoma.&amp;publication_year=2020&amp;journal=Ther+Adv+Med+Oncol&amp;pages=1758835920907504-1758835920907504&amp;doi=10.1177%2F1758835920907504&amp;pmid=32215057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">McKay RR, Bossé D, Choueiri TK. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma. <em>J Clin Oncol</em> 2018 October 29 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.79.0253" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30372392/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453684800013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evolving+systemic+treatment+landscape+for+patients+with+advanced+renal+cell+carcinoma.&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;doi=10.1200%2FJCO.2018.79.0253&amp;pmid=30372392" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines insights: kidney cancer, version 1.2021. <em>J Natl Compr Canc Netw</em> 2020;18:1160-1170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.6004/jnccn.2020.0043" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32886895/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577833900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=NCCN+Guidelines+insights%3A+kidney+cancer%2C+version+1.2021.&amp;publication_year=2020&amp;journal=J+Natl+Compr+Canc+Netw&amp;pages=1160-1170&amp;doi=10.6004%2Fjnccn.2020.0043&amp;pmid=32886895" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Bedke J, Albiges L, Capitanio U, et al. Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. <em>Eur Urol</em> 2020 December 20 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33357997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000694859600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+European+Association+of+Urology+guidelines+on+renal+cell+carcinoma%3A+nivolumab+plus+cabozantinib+joins+immune+checkpoint+inhibition+combination+therapies+for+treatment-na%C3%AFve+metastatic+clear-cell+renal+cell+carcinoma.&amp;publication_year=2020&amp;journal=Eur+Urol&amp;pmid=33357997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <em>Lancet Oncol</em> 2015;16:1473-1482.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(15)00290-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26482279/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000364470900030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvatinib%2C+everolimus%2C+and+the+combination+in+patients+with+metastatic+renal+cell+carcinoma%3A+a+randomised%2C+phase+2%2C+open-label%2C+multicentre+trial.&amp;publication_year=2015&amp;journal=Lancet+Oncol&amp;pages=1473-1482&amp;doi=10.1016%2FS1470-2045%2815%2900290-9&amp;pmid=26482279" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] everolimus alone as second-line treatment. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] safety profiles for each combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Lee J-L, Ziobro M, Suarez C, et al. First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): updated follow-up for KEYNOTE-427 cohort B. <em>J Clin Oncol</em> 2020;38:Suppl:5034-5034. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2020.38.15_suppl.5034" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+pembrolizumab+%28pembro%29+monotherapy+in+advanced+non-clear+cell+renal+cell+carcinoma+%28nccRCC%29%3A+updated+follow-up+for+KEYNOTE-427+cohort+B.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=5034-5034&amp;doi=10.1200%2FJCO.2020.38.15_suppl.5034" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Taylor MH, Lee C-H, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. <em>J Clin Oncol</em> 2020;38:1154-1163.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.01598" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31961766/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000526811600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+IB%2FII+trial+of+lenvatinib+plus+pembrolizumab+in+patients+with+advanced+renal+cell+carcinoma%2C+endometrial+cancer%2C+and+other+selected+advanced+solid+tumors.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=1154-1163&amp;doi=10.1200%2FJCO.19.01598&amp;pmid=31961766" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] treated patients with renal cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the results of phase 1 dose-finding trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] safety profiles for each combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. <em>J Clin Oncol</em> 1984;2:187-193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.1984.2.3.187" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6699671/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1984SG68700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Karnofsky+performance+status+revisited%3A+reliability%2C+validity%2C+and+guidelines.&amp;publication_year=1984&amp;journal=J+Clin+Oncol&amp;pages=187-193&amp;doi=10.1200%2FJCO.1984.2.3.187&amp;pmid=6699671" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. <em>J Clin Oncol</em> 2002;20:289-296.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2002.20.1.289" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11773181/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000173231900037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon-alfa+as+a+comparative+treatment+for+clinical+trials+of+new+therapies+against+advanced+renal+cell+carcinoma.&amp;publication_year=2002&amp;journal=J+Clin+Oncol&amp;pages=289-296&amp;doi=10.1200%2FJCO.2002.20.1.289&amp;pmid=11773181" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Molina AM, Hutson TE, Larkin J, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). <em>Cancer Chemother Pharmacol</em> 2014;73:181-189.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00280-013-2339-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24190702/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329223200021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+1b+clinical+trial+of+the+multi-targeted+tyrosine+kinase+inhibitor+lenvatinib+%28E7080%29+in+combination+with+everolimus+for+treatment+of+metastatic+renal+cell+carcinoma+%28RCC%29.&amp;publication_year=2014&amp;journal=Cancer+Chemother+Pharmacol&amp;pages=181-189&amp;doi=10.1007%2Fs00280-013-2339-y&amp;pmid=24190702" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content"><em>Lenvima (lenvatinib)</em>. Woodcliff Lake, NJ: Eisai, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvima+%28lenvatinib%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the results of phase 1 dose-finding trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] safety profiles for each combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. <em>Stat Biopharm Res</em> 2013;5:311-320.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19466315.2013.807748" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327394600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple+testing+in+group+sequential+trials+using+graphical+approaches.&amp;publication_year=2013&amp;journal=Stat+Biopharm+Res&amp;pages=311-320&amp;doi=10.1080%2F19466315.2013.807748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content"><em>Keytruda (pembrolizumab)</em>. Whitehouse Station, NJ: Merck Sharp &amp; Dohme, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Keytruda+%28pembrolizumab%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content"><em>Afinitor (everolimus)</em>. East Hanover, NJ: Novartis Pharmaceuticals, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Afinitor+%28everolimus%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. <em>J Clin Oncol</em> 2020;38:2981-2992.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.02627" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32167863/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000574584300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvatinib+plus+pembrolizumab+in+patients+with+advanced+endometrial+cancer.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=2981-2992&amp;doi=10.1200%2FJCO.19.02627&amp;pmid=32167863" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2020;21:1563-1573.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(20)30436-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33284113/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000599899200040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+axitinib+versus+sunitinib+monotherapy+as+first-line+treatment+of+advanced+renal+cell+carcinoma+%28KEYNOTE-426%29%3A+extended+follow-up+from+a+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet+Oncol&amp;pages=1563-1573&amp;doi=10.1016%2FS1470-2045%2820%2930436-8&amp;pmid=33284113" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibitor–containing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inhibitor–containing regimens. </span></a></li></ul></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 14, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2107518" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 13, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2101777" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Step Ahead in Metastatic Renal Cell Carcinoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A. Ravaud</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Boston, Massachusetts</span></div><div><span>Emergency Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891702/chair-department-of-emergency-medicine-beth-israel-deaconess-medical-center-boston-ma/?query=fjwp&amp;rid=458565">CHAIR - DEPARTMENT OF EMERGENCY MEDICINE - Beth Israel Deaconess Medical Center, Boston, MA</a></div></div><div class="nejm-widget_item"><div><span> Lebanon, New Hampshire</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/875706/academic-general-neurologist/?query=fjwp&amp;rid=217510">Academic General Neurologist</a></div></div><div class="nejm-widget_item"><div><span> Iowa</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885191/family-medicine-w-women-s-health-focus-360k-earning-thriving-ia-community/?query=fjwf&amp;rid=5263">Family Medicine w/ Women's Health Focus | $360K+ Earning | Thriving IA Community</a></div></div><div class="nejm-widget_item"><div><span> Dayton, Ohio</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890361/sport-medicine-physician-supportive-team-/?query=fjwf&amp;rid=346908">Sport Medicine Physician - Supportive Team!</a></div></div><div class="nejm-widget_item"><div><span> Muncie, Indiana</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/876646/nocturnist-hospitalist-established-program-open-icu-specialist-support/?query=fjwf&amp;rid=227325">Nocturnist, Hospitalist- Established Program, Open ICU, specialist support</a></div></div><div class="nejm-widget_item"><div><span> Portland, Oregon</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891360/hospitalist/?query=fjwf&amp;rid=329661">Hospitalist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035716&amp;pubId=41289505&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d676f5c713f24b-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d676f5c713f24b-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d676f5c713f24b-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$326193401$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$326193401$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$326193401$--></div></div><div class="mlt-body"><!--?lit$326193401$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$326193401$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$326193401$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$326193401$-->Feb 03, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2108330?query=recirc_Semantic" target="_self">Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer</a></div><div class="mlt-article-authors"><!--?lit$326193401$-->V. Makker and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$326193401$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$326193401$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$326193401$-->Aug 22, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2313906?query=recirc_Semantic" target="_self">Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$326193401$-->T.K. Choueiri and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$326193401$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$326193401$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$326193401$-->Apr 18, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312695?query=recirc_Semantic" target="_self">Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$326193401$-->T.K. Choueiri and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$326193401$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$326193401$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$326193401$-->Aug 19, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2106391?query=recirc_Semantic" target="_self">Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$326193401$-->T.K. Choueiri and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$326193401$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$326193401$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$326193401$-->Jan 02, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401726?query=recirc_Semantic" target="_self">Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$326193401$-->A.B. Apolo and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2035716?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2035716" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035716.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2035716"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2034060" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Beyond the Rubble of Lake Street — Minds in Crisis in a City in Crisis</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2032510" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f1.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/67b0cb54-4861-4465-8bb4-e241e025fc50/assets/images/large/nejmoa2035716_f1.jpg" height="3065" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Panel A shows the Kaplan–Meier curves for progression-free survival in each treatment group. Tick marks indicate censored data. Panel B shows the analysis of progression-free survival in subgroups of patients in the lenvatinib-plus-pembrolizumab group and the sunitinib group. Progression-free survival was assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent review committee. Differences between the treatment groups were evaluated with the stratified log-rank test, stratified according to geographic region and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk group. A stratified Cox regression model was used to estimate the hazard ratio for disease progression or death and 95% confidence intervals (CIs). MSKCC and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups are defined in the <a href="#ap2">Supplementary Appendix</a>. Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability. The programmed cell death ligand 1 (PD-L1) combined positive score is defined as the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035716_f2.jpg"><img src="/cms/10.1056/NEJMoa2035716/asset/99e0f0f6-c8fb-4199-8345-a60705f5486a/assets/images/large/nejmoa2035716_f2.jpg" height="2280" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival and Duration of Response.</div><div class="notes"><div role="doc-footnote">Panel A shows the Kaplan–Meier curves for overall survival, and Panel B shows the Kaplan–Meier curves for the duration of response in patients who had a response. Tick marks indicate censored data. NE denotes could not be estimated, and NR not reached.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Confirmed Tumor Responses.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events of Any Cause That Emerged or Worsened during Treatment in at Least 25% of the Patients in Any Treatment Group.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/14" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 14</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 08, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2032510" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">O.L. Schjørring and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 08, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2007123" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.J.A. Jenkins and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 08, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2027760" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Sutimlimab in Cold Agglutinin Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A. Röth and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2035716%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035716&amp;pubId=41289505&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2035716%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035716&amp;pubId=41289505&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06699321739667508" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d676f5c713f24b-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d676f5c713f24b-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d676f5c713f24b-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d676f5c713f24b-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d676f5c713f24b-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d676f5c713f24b-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d676f5c713f24b-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d676f5c713f24b-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d676f5c713f24b-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d676f5c713f24b-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d676f5ba6cf24b',t:'MTc0OTUzMzMwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d676f5ba6cf24b&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><htw-skmsshldyrmn></htw-skmsshldyrmn><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2035716?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-transactionid="dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" id="captureIFrame_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" target="captureIFrame_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="capture_screen"><input id="capture_signIn_js_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="js_version"><input id="capture_signIn_transactionId_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" type="hidden" class="capture_transactionId_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="capture_transactionId"><input id="capture_signIn_form_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="form"><input id="capture_signIn_flow_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="flow"><input id="capture_signIn_client_id_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="client_id"><input id="capture_signIn_redirect_uri_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="redirect_uri"><input id="capture_signIn_response_type_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="response_type"><input id="capture_signIn_flow_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="flow_version"><input id="capture_signIn_settings_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="settings_version"><input id="capture_signIn_locale_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="locale"><input id="capture_signIn_recaptcha_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_dmrvhbivfu7z4b033f56le75l7rz51e2ooz3fu02" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>